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Abstract 
Mia-Lisa Schmiedt. The CLN5 disease – maturation, trafficking and pathology. 
National Institute for Health and Welfare (THL). Research 84/2012. 174 pages. 
Helsinki, Finland 2012. 
ISBN 978-952-245-677-9 (printed); ISBN 978-952-245-678-6 (pdf) 
 
Neurodegenerative disorders are caused by defects in the central nervous system 
leading to neuronal destruction and devastating conditions. They are often incurable 
and result in premature death. Neuronal ceroid lipofuscinoses (NCLs) comprise a 
group of rare, hereditary neurodegenerative disorders. They belong to the family of 
lysosomal storage disorders primarily affecting children. Patients share common 
features like accumulation of autofluorescent storage material, neuronal degenera-
tion, and suffer from motor disturbances, progressive loss of vision and premature 
death. To date, nine genes have been detected to cause NCLs, but the mechanisms 
and functions of the proteins encoded by these genes are still largely unknown. 
One type of NCLs is the CLN5 disease, a late infantile variant phenotype form. This 
severe neurodegenerative disease of childhood is caused by mutations in the CLN5 
gene, which encodes a highly glycosylated lysosomal protein of unidentified func-
tion. The early years of the patients are in most cases normal. First clinical signs 
usually start between 4-7 years of age with psychomotor disturbances and visual 
impairment. The disease often progresses rapidly between the ages 9-11 years and 
from the age of 12 years patients require help with all activities. Patients die young 
mostly between 12 to 23 years of age. 
The aim of this thesis project was to contribute to the understanding of the molecular 
and cell biological mechanisms underlying CLN5 disease. Thereby, the focus of the 
first part of the thesis was on the basic characterisation of the maturation and traf-
ficking of the CLN5 protein by in vitro studies. Thorough analyses presented proteo-
lytical cleavage of a predicted CLN5 signal peptide in the ER, subsequent matura-
tion/trimming of the proform followed by trafficking to the lysosomes. First evi-
dence indicated that CLN5 might also use mannose-6-phosphate receptor independ-
ent trafficking routes to the lysosomes. 
Overexpression studies of CLN5 constructs carrying different disease causing muta-
tions revealed that trafficking was disturbed with varying severity depending on the 
particular mutation. Moreover, the trafficking to lysosomes could be rescued by co-
expression of another NCL protein CLN1/PPT1, a suggested interaction partner of 
CLN5. 
Real-time PCR revealed that Cln5 gene expression rises gradually in the mouse 
brain with age and its expression is highest in microglia, the so called macrophages 
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of the brain which are important for the immune system of the central nervous sys-
tem (CNS). Further, mice lacking the Cln5 gene (Cln5 ko) were utilised to study the 
pathology in more detail. Early microglial activation in Cln5 ko mice was doc-
umented by immunohistochemical staining and thresholding image analysis. Early 
defective myelination was also observed in vitro and in vivo, prominently in the 
superficial laminae of the cortex but not in white matter structures. Additionally, 
disturbances in the systemic lipid metabolism and lipid transport were detected, 
pinpointing to a possible role of Cln5 in lipid homeostasis/transport. 
Another goal of this thesis project was to investigate possible in vivo links between 
Cln5 and its suggested interaction partner palmitoyl protein thioesterase (Cln1/Ppt1), 
also a member of NCL proteins. Mutations in the CLN1 gene are known to cause an 
infantile form of NCL. Cln1- and Cln5-deficient mice were crossed, thereby gener-
ating Cln1/Cln5-double-knockout (Cln1/5 dko) mice, which were then characterised 
with the ultimate goal to provide novel insights into NCLs in general. The pathology 
of Cln1/5 dko mice was more severe than in the single knockout animals, with wide-
spread accumulation of autofluorescent storage material in the brain, intense astro-
cytosis and microglial activation especially in the thalamus and cortical regions, 
defective myelination in the cortex and disturbed lipid metabolism. Gene expression 
profiling of the cortex of Cln1/5 dko mice underlined these findings pointing at de-
fects in myelination and immune response pathways.  
In conclusion, this thesis work elucidates the controversially discussed maturation 
and localisation of the CLN5 protein. It provides novel aspects about the early 
events in the pathogenesis of CLN5 disease, late infantile variant, links Cln5 to lipid 
metabolism and strengthens the recently reported connection to Cln1/Ppt1. To-
gether, the findings of this thesis work contribute to the basic knowledge of molecu-
lar mechanisms underlying these devastating diseases. 
 
 
 
 
 
 
Keywords: CLN5, Neuronal Ceroid Lipofuscinosis, protein maturation, trafficking, 
microglial activation, oligodendrocytes, lipid homeostasis 
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ABCA/G ATP-binding cassette transporter family A/G 
ATP adenosine triphosphate 
BBB blood brain barrier 
BFA brefeldin A 
BODIPY-LacCer boron dipyrromethene-lactoceramide 
BSA bovine serum albumin 
Cc corpus callosum 
CD68 cluster of differentiation 68  
cDNA complementary DNA 
Chx cycloheximide 
Chol cholesterol 
CL curvilinear profile 
CLN1-10, CLN1-10 ceroid lipofuscinosis, neuronal 1-10, human protein, DNA/RNA 
Cln1-10, Cln1-10 ceroid lipofuscinosis, neuronal 1-10, murine protein, DNA/RNA 
Cln1 ko, Cln5 ko Cln1-deficient knockout mice, Cln5-deficient knockout mice 
Cln1/5 dko Cln1/d-deficient double-knockout mice 
CNPase 2’,3’-cyclic nucleotide 3’-phosphohydrolase 
CNS central nervous system 
COS-1 cells African green monkey kidney cells 
CSF cerebrospinal fluid 
DAB 3,3′-diaminobenzidine tetrahydrochloride HCl 
DMEM Dulbecco’s modified Eagle´s medium 
DNA deoxyribonucleic acid  
DPX p-xylene-bis(pyridinium bromide) 
EB embryoid body 
ECL enhanced chemiluminescence 
EM electron microscopy 
EndoH endoglycosidase H 
ER endoplasmic reticulum 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FP fingerprint profile 
GABA gamma-aminobutyric acid 
GalCer galactosylceramide 
GalNAc N-acetylgalactosamine 
GFAP glial fibrillary acidic protein 
GFP green fluorescent protein 
Glc glucose 
GROD  granular osmiophilic deposits 
GSL glycosphingolipid 
HDL, LDL, VLDL high, low, very low density lipoprotein 
HeLa cells human cervical tumour cells 
IBA-1 ionised calcium adaptor protein 1 
ic internal capsule 
if/IF intermediate filament (if); immunofluorescence (IF) 
iPS induced pluripotent stem cells 
kDa kilodalton(s) 
LAMP-1 lysosomal associated membrane protein 
LCAT lecithin:cholesterol acyltransferase 
 
 
THL — Research 84/2012 14 The CLN5 disease - protein  maturation, trafficking and pathology 
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LIMP-2 lysosomal integral membrane protein 
LPS Escherichia coli lipopolysaccharide 
LSD lysosomal storage disorder 
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1 Introduction  
Neurodegeneration is an umbrella term for progressive loss of neurons. Various 
acquired and inherited diseases of the central nervous system (CNS) are caused by 
neurodegenerative events, including e.g. Alzheimer’s and Parkinson’s diseases (AD, 
PD). Neurodegenerative disorders are usually incurable and are connected to high 
expenses for the health care system, dramaticically diminished quality of life, in-
firmity and death. Regarding these aspects, development of treatments is of utter-
most importance. The reasons for neuronal death are complex and often difficult to 
elaborate. Studies on monogenic diseases involving neurodegeneration, like neu-
ronal ceroid lipofuscinoses (NCLs), may further the understanding of neuronal death 
in neurodenerative diseases and help to develop treatments. 
NCLs comprise a group of recessively inherited neurodegenerative disorders affect-
ing mainly children. The first clinical description of any NCL reaches back to 1826 
by Dr. Otto Christian Stengel in Norway (Haltia, 2006). Hitherto, at least nine genes 
are known to underlie this group of disorders (Kousi et al., 2012; Noskova et al., 
2011). Degeneration of nerve cells and accumulation of autofluorescent ceroid-
lipopigment in neural and peripheral tissues are two histopathological characteristics 
of NCLs (Goebel, 1997). One form of NCLs is the CLN5 disease, late infantile vari-
ant form formerly known as Finnish variant late infantile neuronal ceroid lipofus-
cinosis, vLINCLFin. This type is caused by mutations in the CLN5 gene and belongs 
to the Finnish disease heritage (Norio, 2003). As the numbers of diagnosed CLN5 
patients other than of Finnish origin have been rising during the last few years, the 
original term vLINCLFin is not appropriate anymore. Patients of various origins have 
been found all over the world: Columbian, Portuguese, French Canadian, Hispanic, 
Swedish, Chinese, Asian Indian, Egyptian and Pakistani ancestry (Bessa et al., 2006; 
Pineda-Trujillo et al., 2005; Xin et al., 2010). To date, the functions of most NCL 
proteins remain unclear including CLN5. CLN5 shows no homology to any other 
known proteins and is evolutionary conserved only among vertebrates. However, 
interactions between NCL proteins, especially between CLN5 and other NCL pro-
teins have been suggested by in vitro studies and comparative gene expression an-
alysis (Lyly et al., 2009; Vesa et al., 2002; von Schantz et al., 2008). Why defects in 
NCL proteins, which vary in function, cell location and solubility, lead to the similar 
pathological endpoint remains elusive. In this thesis, the aim was to elucidate the 
basic properties of the CLN5 protein, deeper analyse the impact of the loss of func-
tion in Cln5-deficient mice and study the affected pathways, when Cln5 and its pre-
dicted interaction partner Cln1/Ppt1 are both simultaneously not functional. 

? 
THL — Research 84/2012 17 The CLN5 disease - protein  maturation, trafficking and pathology 
 
2 Review of the literature 
2.1 Lysosomes and lysosomal storage disorders 
2.1.1 Intracellular membrane trafficking pathways 
All eukaryotic cells are surrounded by a membrane that functions as a barrier be-
tween the inside cell components and its environment. The inside of a cell is further 
organised into compartments each surrounded by its own membrane. One way of 
communication between these compartments, also named organelles, is via traffick-
ing vesicles which transport proteins and lipids. The main events of vesicular traf-
ficking can be divided into several steps: sorting of the cargo, vesicle formation, 
subsequent transport along the cytoskeleton, detection of the target organelle, finally 
membrane fusion and release of the cargo (van Vliet et al., 2003). In general, pro-
teins contain signal sequences which determine their localisation within the cell (van 
Vliet et al., 2003). Lipids are hypothesised to contain target information within their 
structure (Haucke and Di Paolo, 2007). 
The endocytic and the secretory pathways are the two major routes of intracellular 
trafficking, which are interconnected via the Golgi complex and endocytic com-
partments (Bonifacino and Rojas, 2006). The endocytic pathway describes an in-
wards directed vesicle-mediated route from the environment into the cell, which is 
generally used for internalisation of extracellular macromolecules, such as lipids and 
proteins. After the cargo has entered the cell, it continues its journey to early 
endosomes from where it is either transported to multivesicular bodies (MVBs), late 
endosomes or lysosomes. Alternatively, it is recycled back to the cell sur-
face/extracellular space via tubular recycling endosomes (Pryor and Luzio, 2009). In 
contrast, the secretory pathway is used to transport cargoes synthesised in the endo-
plasmic reticulum (ER) and Golgi complex to the cell surface, to endosomes and/or 
lysosomes or to the extracellular space. Disturbances in the intracellular transport 
can lead to severe dysfunctions of tissue and organs. For example, about 50 lyso-
somal diseases are known to be caused by dysfunctional cargo transport. 
2.1.2 The lysosome and its function within the cell 
Lysosomes embody one of the major degradative and catabolic compartments in 
eukaryotic cells. They are the so called waste disposal system of cells as they are 
able to degrade extracellular material that has been internalised (e.g. microbes) and 
recycle cellular molecules. 1955 Christian de Duve first described lysosomes as 
membrane-closed compartments with acid phosphatase activity (De Duve et al., 
2 Review of the literature 
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1955). Alex Novikoff displayed the first morphological presentation of lysosomes 
by transmission electron microscopy (Novikoff et al., 1956). The existence of a 
single phospholipid bilayer surrounding the lysosomes and globular and tubular 
shapes has been confirmed shortly after that. Lysosomes appear electron-dense in 
electron micrographs, often include irregularities and membrane sheets, and the 
content can highly vary (Saftig and Klumperman, 2009). The vacuolar H1-ATPase, a 
large transmembrane multiprotein complex plays a key role in the maintenance of 
the acidic interior with a pH of 4.5–5 (Marshansky and Futai, 2008). Lysosomes 
contain more than 50 different acid hydrolases (e.g. proteases, phosphatases, glyco-
sidases, lipases, nucleases, sulfatases) that are capable of degrading macromolecules 
and even membranes into their monomeric components in this acidic environment 
(Schröder et al., 2010). Studies on lysosomal membrane proteins (LMPs) have been 
quite demanding due to the hydrophobic nature of LMPs. Currently, the number of 
predicted lysosomal membrane proteins range from hundred to several hundred 
(Lubke et al., 2009; Schröder et al., 2010). LMPs are involved in the establishment 
and maintenance of the pH gradient between cytoplasm and lysosomal lumen, hy-
drolase compartmentalisation, membrane fusion and transport (Saftig et al., 2010). 
Additionally, lysosomes contain various transporters that are involved in the export 
of lysosomal catabolites from the lysosomal lumen to the cytosol or import macro-
molecules for degradation (Schröder et al., 2010). 
The biogenesis of lysosomes has been extensively studied and a number of models 
have been described: the maturation model (lysosomes mature from endosomes), the 
vesicular transport model (vesicles distribute cargo between endosomes and lyso-
somes), the kiss-and-run model (cargo is exchanged by transient contacts, “kisses”, 
between endosomes and lysosomes and then disscociate “run” again), the direct 
fusion model (endosomes and lysosomes fuse to a hybrid organelle) and the fusion-
fission model (a mixture between direct fusion and kiss-and-run: lysosomes and 
endosomes fuse permanently, form a hybrid organelle and subsequently lysosomes 
re-form from hybrid organelles again) (Luzio et al., 2007) (Figure 1).  
The capability of lysosomes to interact and fuse with other cell compartments like 
late endosomes, autophagosomes, phagosomes and even the plasma membrane has 
been well established (Luzio et al., 2007). These events take place via complex pro-
tein-protein interactions and are highly dynamic (Saftig and Klumperman, 2009). 
For instance, endocytosed and newly synthesised macromolecules are transported to 
lysosomes by kissing events and direct fusion. The resulting hybrid organelles act as 
degradation compartments of endocytosed macromolecules and lysosomes are re-
formed from the hybrid organelle by maturation (Luzio et al., 2007). The basic char-
acteristics of lysosome fusion with the plasma membrane and with late endosomes 
have been extensively studied, but how these processes are precisely regulated re-
quires further investigation. 
2 Review of the literature 
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Figure 1: proposed models for biogenesis of lysosomes and how cargo is delivered 
to lysosomes. In the first step, endocytic cargo is internalised from the plasma mem-
brane to early endosomes (EE) and then to late endosomes (LE). A. In the maturation 
model, endosomes mature into lysosomes (L) by gradual addition of lysosomal compo-
nents. B. The second model postulates that EE, LE and lysosomes are separate and stable 
compartments and cargo is transferred through an endosomal carrier vesicle (ECV)/ 
multivesicular body (MVB). C. In the third model LE and lysosomes transiently fuse, 
exchange material and depart again. D. The fusion fission model is a mixture of kiss-
and-run and direct fusion. 
Abbreviations: CV, cargo vesicle; ECV, endosomal carrier vesicle; EE, early endosome; 
L, lysosome; LE, late endosome, MVB, multivesicular body; RV, recycling vesicle. 
Adapted from Luzio et al., 2007; Mullins and Bonifacino, 2001. 
 
2.1.3 Lysosomal targeting of proteins 
It is of great importance for the lysosomal function that lysosomal proteins are cor-
rectly targeted to their destination (Braulke and Bonifacino, 2009).  
Soluble lysosomal proteins are synthesised as pre-pro-proteins with an N-terminal 
signal sequence (20-25 aa), which translocates the precursor protein into the lumen 
of the endoplasmic reticulum (ER) (Hasilik et al., 2009). The signal peptides are 
removed and initial protein glycosylation takes place. The signal motif for N-
glycosylation is Asn-X-Ser/Thr (x: any amino acid except proline) and is evolution-
ary conserved (Braulke and Bonifacino, 2009). The oligosaccharide branch 
Glc3Man9(GlcNAc)2 is attached to the amino group of the asparagine side chain 
amide and processed and modified in the ER and Golgi apparatus. Mature glycopro-
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teins can contain three different types of N-glycans: high mannose, complex and 
hybrid sugars. Another post-translational modification taking place in the Golgi 
complex is O-glycosylation, where sugar residues can be transferred to the OH-
group of an amino acid side chain, mostly of serine or threonine. This type of glyco-
sylation is a single monosaccharide transfer process initiated by specific GalNAc 
transferases (over 24 described). In contrast to N-glycosylation, O-glycosylation is 
not known to take place at a single consensus sequence. However, the various Gal-
NAc transferases are highly specific and control the glycosylation process. Addition 
and modification of sugar residues also play an important role in protein folding, 
quality control and transport (Helenius and Aebi, 2001; Ruddock and Molinari, 
2006). 
In the Golgi apparatus, soluble lysosomal proteins usually undergo further modifica-
tions which are important for the lysosomal targeting (Figure 2). For example, most 
lysosomal hydrolases obtain mannose-6-phosphate (M6P) residues in their oligosac-
charide chains by the sequential action of two enzymes, the GlcNac-1-
phosphotransferase and N-acetylglucosamine-1-phosphodiester α-N-acetyl-
glucosaminidase (uncovering enzyme, UCE) (Coutinho et al., 2011). This is specific 
for N-glycans and has not been reported for O-glycans (Durand and Seta, 2000). 
Soluble lysosomal proteins can later be recognised and bound by their M6P residues 
in the trans-Golgi network (TGN) by two type I transmembrane (single-pass trans-
membrane proteins with the N-terminus exposed to the extracellular or luminal 
space and the C-terminal part located on the cytoplasmic side) mannose-6-phosphate 
receptors of 46kD (MPR46, cation-dependent MPR, dimer) and 300kD (MPR300, 
cation-independent MPR, monomer) (Figure 2) (Ghosh et al., 2003). The recogni-
tion of cargo (soluble lysosomal proteins) by the two MPRs is distinct but overlap-
ping concerning intracellular targeting (Qian et al., 2008). The soluble lysosomal 
protein-MPR complexes exit the TGN in clathrin coated vesicles associated either 
with GGA proteins (Golgi-localised, γ-ear-containing, Arf (ADP-ribosylation fac-
tor)-binding proteins) or AP-1 (adaptor protein-1), which recognise and select dif-
ferent cargoes and assist incorporation of targeting/fusion proteins to transport vesi-
cles (Daboussi et al., 2012). The transport vesicles then fuse with the endocytic 
system (Figure 2) (Doray et al., 2002; Puertollano et al., 2003). The low pH in 
endosomes leads to the dissociation of the soluble lysosomal protein-MPR complex 
and the receptors can be recycled and transferred back to the TGN via two predicted 
pathways involving a multiprotein complex (retromer) and Rab9-TIP47 (Rab9, 
small GTPase; TIP47, tail interacting protein of 47kD) (Figure 2). However, the 
involvement of TIP47 in the retrograde trafficking of MPRs from endosomes to the 
TGN is discussed controversially (Braulke and Bonifacino, 2009; Bulankina et al., 
2009). Lysosomes do not contain MPRs which differentiates these organelles from 
endosomal compartments. A fraction of the MPRs are located at the plasma mem-
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brane, where they deliver enzymes from the extracellular space towards lysosomes 
(Figure 2) (Braulke and Bonifacino, 2009). 
In the past years, more and more soluble lysosomal proteins have been described to 
traffic to lysosomes in an MPR-independent manner. One alternative route is via 
sortilin, a 95kD type I transmembrane protein, which is acting as a sorting receptor 
for sphingolipid activator proteins (SAPs), cathepsin D and H, acid sphingomyeli-
nase and nerve growth factor precursor (pro-NGF) (Canuel et al., 2008; Chen et al., 
2005; Lefrancois et al., 2003; Ni and Morales, 2006). Sortilin is retrieved from 
endosomes to the TGN by the retrograde transport machinery (Kim et al., 2010). 
Also, the lysosome-integral membrane protein 2 (LIMP-2), a type III (multipass) 
transmembrane protein, has been shown to mediate the lysosomal targeting of β-
glucocerebrosidase (Reczek et al., 2007). Whether LIMP-2 is recycled between 
endosomes and the TGN like MPRs is currently not known. 
In contrast to soluble lysosomal proteins, lysosomal membrane proteins contain 
sorting signals in their sequence of the cytoplasmic tails and are independent from 
MPRs. The signals usually mediate both lysosomal destination and endocytosis from 
the extracellular space. Two pathways, the direct and indirect route, have been sug-
gested for lysosomal membrane proteins (Braulke and Bonifacino, 2009). The direct 
route refers to trafficking of lysosomal membrane proteins from the TGN to 
early/late endosomes and then directly to lysosomes (Figure 2). In the indirect 
pathway, the lysosomal membrane proteins traffic constitutively from the TGN to 
the cell surface, and then are internalised into early endosomes and subsequently 
transported to late endosomes/lysosomes (Figure 2). Lipid modifications have also 
been suggested to contribute to lysosomal targeting (Braulke and Bonifacino, 2009). 
For example, C-terminal prenylation of the transmembrane NCL protein CLN3 has 
been shown to be involved in the sorting from endosomes to lysosomes (Storch et 
al., 2007).  
For internalised proteins, which are targeted to lysosomes for degradation, there are 
different routes to reach their destination. Some endocytosed proteins, like low-
density lipoprotein, detach from their receptors in the early endosomes due to the 
acidic pH and are subsequently degraded in the lysosomes. The free receptors can 
then recycle back to the plasma membrane. Other ligands, like epidermal growth 
factor (EGF), do not dissociate from their receptors. The receptor-ligand-complexes, 
which are ubiquitinylated, are endocytosed from the cell surface and internalised 
into luminal vesicles. Subsequently, late endosomes which contain these vesicles 
fuse with lysosomes (Luzio et al., 2007). 
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Figure 2: sorting of lysosomal proteins. 1. Lysosomal proteins are synthesised at the 
endoplasmic reticulum (ER) and transported to the Golgi apparatus. At the trans-Golgi 
network (TGN), some soluble lysosomal proteins obtain a mannose-6-phosphate (M6P)-
modification and bind to mannose-6-phosphate receptors (MPRs: MPR46 or MPR300), 
while others are recognised by sortilin or LIMP-2, like e.g. the β-glucocerebrosidase. 2. 
The enzyme-receptor complexes and lysosomal transmembrane proteins concentrate in 
clathrin/GGA/AP-1-coated dense areas of the TGN, from where clathrin-coated carriers 
transport them to endosomes. 3. Acidic pH induced dissociation of the enzyme-receptor 
complexes in the endosomes. 4. MPR and sortilin are retrieved from endosomes to the 
TGN by retrograde transport machinery that, among various components, includes 
retromer and maybe TIP47 (tail interacting protein of 47kD). 5. LIMP-2 remains as a 
component of the lysosomal membrane. 6. A part of the MPRs, and possibly some of the 
other receptors/lysosomal transmembrane proteins, are transferred from the TGN to the 
plasma membrane (PM). 7. The cell surface located receptors deliver enzymes from the 
extracellular medium to endosomes and consequently to lysosomes.  
AP-1/-2, adaptor-protein; EE, early endosome; GGA, Golgi-localised, γ-ear-containing, 
Arf (ADP-ribosylation factor)-binding proteins); LE, late endosome; ME, maturing 
endosome; MVB, multivesicular body; N, nucleus. Some elements of the figure were 
produced using Servier Medical Art (www.servier.com). Modified from Braulke and 
Bonifacino, 2009. 
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2.1.4 Lysosomal storage disorders 
Lysosomal function and lysosomal turnover of macromolecules are of great import-
ance for cellular homeostasis. Lysosomal storage disorders (LSDs) comprise a group 
of metabolic disorders caused by mutations in lysosomal enzymes, lysosomal inte-
gral membrane proteins, and proteins playing a role in the post-translational modifi-
cation/trafficking to lysosomes (Schultz et al., 2011). LSDs are recessively inher-
ited, monogenic and the diseases are progressive (Futerman and van Meer, 2004). 
One hallmark of LSDs is the accumulation of un- or partially degraded catabolic 
macromolecules, leading to cellular dysfunction and consequently clinical symp-
toms. Age of onset and clinical manifestations can vary greatly among LSD patients 
with congenital, infantile, juvenile and adult forms, but most patients appear clini-
cally normal at birth. Historically, the subtypes of LSDs were classified on the basis 
of the related accumulated substrate including sphingolipidoses, mucolipidoses, 
mucopolysaccharidoses (MPS), lipoprotein storage disorders, lysosomal transport 
defects, neuronal ceroid lipofuscinoses (NCLs) to list a few of them. Once the role 
of the affected protein is defined, the reason for the accumulated storage material 
often becomes apparent, e.g. defective proteins in Niemann-Pick type C1/2 
(NPC1/2) diseases result in cholesterol accumulation as they are involved in choles-
terol transport from the lysosome (Tang et al., 2010). Another example are muco-
polysaccharidoses (MPS), where proteoglycans are the accumulating storage ma-
terial, being substrates for the defective proteins (Schultz et al., 2011). In contrast, 
the cause of neuronal ceroid lipofuscinoses (NCLs) is still unclear, as it was not 
possible to find direct links between the defective proteins and the accumulating 
storage material as will be discussed in more detail later. 
The clinical phenotype of LSD patients is very diverse ranging from severe neuro-
pathology including dementia and seizures (NCLs) to symptoms confined to periph-
eral tissue (Fabry disease). The exact diagnosis can be challenging as genotype-
phenotype correlations can be incorrect as in some cases the same genetic back-
ground and mutation can present a different clinical outcome. For example, only few 
Gaucher disease patients exhibit neurological symptoms which is surprising as this 
disease belongs to the sphingolipidoses and the levels of glycosphingolipids is en-
riched within the brain. The disease phenotype, severity and progression may be 
affected by secondary pathways, other genes or even environmental factors which 
complicate an exact prognosis and choice of treatment. 
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2.2 Key players of the central nervous system (CNS) 
2.2.1 Cells of the CNS and their functions 
The central nervous system is a very complex organ system containing a variety of 
cell types networking together to receive, process, integrate and react to the incom-
ing information and to coordinate the activity of all body parts together with the 
peripheral nervous system (PNS). The so called neuronal doctrine was coined by 
Wilhelm von Waldeyer-Hartz based on the work of Ramón y Cajal and others in 
1891 (Guillery, 2007). It places neurons at the centre of the CNS and considers glial 
cells such as oligodendrocytes, microglia and astrocytes to be passive supportive 
cells and not being involved in any informational exchange. The neuronal doctrine 
has been more and more questioned in the recent years (Bullock et al., 2005). Today 
it is known that neurons are not the only functional units in the nervous system but 
glial cells, such as astrocytes, are also able to communicate with themselves and 
with neurons via gap junctions and chemical signalling (Giaume et al., 2010). 
??????? ????????
Neurons, also named nerve cells, are well studied cells, which transmit and process 
information by electrical and chemical signalling. They vary in shape, size and 
length, which determine their functions. In addition, their localisation within the 
brain is also important for their function. In general, neurons consist of a soma, the 
cell body; dendrites, which are thin structures that start from the soma and can be 
long and highly branched; and finally a single axon that extends from the soma at a 
special site, the axon hillock. There are many possible subclassifications of neurons 
based on the shape, number of neurites, dendrites, connections, axon length and 
neurotransmitters (described in Bear et al., 2007).  
During development of the mammalian CNS neural stem cells generate neurons and 
two types of glial cells (astrocytes and oligodendrocytes) (Gotz and Huttner, 2005), 
and the nervous system derives from the ectoderm, the outermost layer of the devel-
oping embryo. The neuroectoderm generates the neural plate along the dorsal side of 
the embryo, and the latter then creates a hollow neural tube. The telencephalon, the 
anterior part of the neural tube, proliferates and expands rapidly to finally give rise 
to the brain. Step by step the proliferating cells differentiate into neurons, astrocytes 
and oligodendrocytes, which then migrate to their final destinations. In the end, the 
neurons extend their axons and dendrites to setup the neuronal network. Neurogen-
esis has been shown to not be restricted to early development but also occurs in 
adult mammals, especially in the hippocampus and subventricular zone (Bonfanti 
and Peretto, 2011). 
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In neuronal signalling, dendrites receive signals which are integrated/processed at 
the soma. Further, the electric signal is transmitted down the axon to the presynaptic 
terminals, where the axon and dendrites of neighbour neurons form synapses. How-
ever, it has been reported that action potentials can also propagate back from the 
axon and soma regions to dendrites (Rapp et al., 1996). 
Most neurons in the nervous system form neuron-neuron connections and are there-
fore called interneurons. Neurons, which contain neurites in the sensory surfaces of 
the body, e.g. the skin or the retina of the eye, are classified as primary sensory neu-
rons. Neurons that form synapses with muscles and transmit movement commands 
are called motor neurons (described in Bear et al., 2007). 
Neurons can also be classified on the basis of the cell shape and dendrites (described 
in Stahl, 2008): for instance, pyramidal cells have a soma shaped like a triangular 
pyramid, shorter basal dendrites, an extensively branched spiny apical dendrite and a 
single axon emerging from the basal pole of the soma (Figure 3A). Most neurons in 
the cerebral cortex are pyramidal neurons, especially in the prefrontal cortex. Purk-
inje cells are located in the cerebellum and contain extensive branched dendritic 
trees from an apical position and an axon from the basal poll (Figure 3B). Basket 
neurons have highly ramified dendritic trees, being cortical interneurons with axons 
spreading horizontally making inhibitory contacts with the soma of other neurons 
(Figure 3C). Double bouquet neurons are also inhibitory interneurons in the cortex, 
resembling two bouquets of flowers in appearance and contain a vertically oriented 
axon (Figure 3D). Spiny neurons have a long axon and dendrites pointing in all 
directions covered with numerous spines (Figure 3E). They are located in the stria-
tum where they receive information from the cortex, thalamus and substantia nigra. 
Finally, chandelier neurons are named after their unique axonal structure resembling 
an old fashioned chandelier and are also inhibitory interneurons in the cortex (Fig-
ure 3F). 
Further, neurons can be classified depending on the number of neurites as unipolar 
(one neurite), bipolar (two neurites) or multipolar (three or more; most neurons). 
Neurons with long axons extending from one part of the brain to another are projec-
tion neurons. Those with short axons, which do not extend the proximity of the soma 
are local circuit neurons. In addition, neurons can be classified based on their neuro-
transmitter chemistry, e.g. cholinergic (neurons that produce and release acetylcho-
line), noradrenergic (norepinephrine), glutamatergic (glutamate), GABAergic 
(GABA) and peptidergic (peptides) (described in Bear et al., 2007). 
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Figure 3: overview of some neurons types. (A) The soma of pyramidal cells is shaped 
like a pyramid. They have a branched spiny apical dendrite, shorter basal dendrites, and 
one axon. Pyramidal neurons constitute the majority of neurons in the cerebral cortex. 
(B) Cerebellar Purkinje cells have extensively ramified dendritic trees and a single axon. 
(C) Cortical basket neurons are inhibitory interneurons with widely ramified dendritic 
trees, which make many contacts with the soma of other neurons. (D) More cortical 
inhibitory interneurons are double bouquet cells. They look like two bouquets of flowers 
and contain a vertically oriented tight bundle of axons and innervate dendrites of other 
cortical neurons. (E) Spiny neurons have dendrites that radiate in all directions and are 
extensively covered with spines. They reside in the striatum and receive input from cor-
tex, thalamus, and substantia nigra. Their axons are long and exit the striatum or return 
as recurrent collaterals to innervate adjacent spiny neurons. (F) Other inhibitory cortical 
interneurons are chandelier neurons. Their axons look like an old-fashioned chandelier 
with axon terminals shaped like vertically oriented cartridges. They inhibit pyramidal 
neuron. Modified from Stahl et al., 2008. 
 
??????? ?????????????????
The efficiency and speed of action potentials depend on the integrity of axons, 
which in turn is dependent on a specialised structure called myelin. Myelin is pro-
duced by oligodendrocytes, which wrap spirals of membrane around axons of multi-
ple neurons in the CNS. Oligodendrocyte biology, myelination and maintenance of 
myelin sheaths are very complex and highly regulated processes (Simons and Trot-
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ter, 2007). During development, oligodendrocyte precursor cells (OPCs) are gener-
ated at multiple foci along the neural tube and divide and migrate throughout the 
CNS. The migration of OPCs is mediated via contacts with extracellular matrix, cell 
surface molecules and secreted molecules. After reaching their final destination 
most oligodendrocytes differentiate into mature myelin-producing oligodendrocytes, 
going through morphological changes and formation of an extensive network of 
branching processes (Figure 4) (Zhang, 2001). However, some OPCs persist into 
adulthood.  
 
 
 
Figure 4: differentiation of oligodendrocytes. The oligodendrocyte differentiation is a 
gradual process of morphological changes. The transformation starts from a bipolar 
oligodendrocyte precursor cell (OPC), to an immature pro-oligodendrocyte (pro-OL) 
with multiple processes, to a mature oligodendrocyte (OL) with membrane-sheaths and 
last to a myelinating OL which can extend its processes to many axons. These transfor-
mation steps can be followed with molecular markers which are sequentially expressed: 
A2B5 antigen, platelet derived growth factor receptor α (PDGFRα) and chondroitin 
sulphate proteoglycan (NG-2) are good OPC and pro-OL markers; O4 antigen marks 
pro-OLs and mature OLs; galactocerebroside, 2’,3’-cyclic nucleotide 3’-
phosphohydrolase (CNPase) marks mature OLs; myelin associated glycoprotein (MAG), 
myelin basic protein (MBP) and proteolipid protein (PLP) are expressed in myelinating 
oligodendrocytes. Some elements of the figure were produced using Servier Medical Art 
(www.servier.com). Modified from Zhang, 2001. 
 
Myelin of peripheral nerves consists of approximately 70-85% lipids and 15-30% 
proteins (Norton, 1981). There are no myelin-specific lipids but the glycosphin-
golipid galactosylceramide, also known as galactocerebroside, is the most character-
istic for myelin (Aggarwal et al., 2011). In the adult brain the galactosylceramide 
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content is proportional to the concentration of myelin. Other major lipids of myelin 
are cholesterol, sphingomyelin and ethanolamine-containing plasmalogens (Aggar-
wal et al., 2011). Also the fatty acid composition of many lipids is characteristic in 
myelin. The proteolipid protein (PLP) and the myelin basic proteins (MBP) are the 
major protein components of the myelin sheath. Other less abundant proteins are e.g. 
the 2′-3′-cyclic nucleotide 3′-phosphohydrolase (CNPase), the myelin-associated 
glycoprotein (MAG) and the myelin-oligodendrocyte glycoprotein (MOG) (Bau-
mann and Pham-Dinh, 2001). MBP is found throughout the thick membraneous 
processes and has been described to be a useful marker to examine myelination de-
fects and differentiation of oligodendrocytes in vivo (Vincze et al., 2008). Further-
more, MBP and CNPase have been predicted to participate in the formation of my-
elin membranes by interactions with the cytoskeleton. MBP is thought to serve as a 
microtubule-stabilising protein (Galiano et al., 2006) and CNPase is suggested to 
induce microtubule assembly and process outgrowth via copolymerisation with 
tubulin (Lee et al., 2005). CNPase is absent in compact myelin but is highly ex-
pressed at the cytoplasmic laminae of plasma membranes of myelinating oligoden-
drocytes and is connected to the cytoskeleton.  
??????? ??????????
Until 1991, the very existence of microglia was under debate. A leading textbook of 
neuropathology doubted this and suggested to abandon the term microglia (Dolman, 
1991). About the same time the idea of a “microglial immune network” in the CNS 
was first proposed (Graeber and Streit, 1990). Nowadays, microglia are considered 
to be a key element in the CNS being involved in the brain and spinal cords innate 
immune system (Graeber and Streit, 2010). In contrast to other glial cells like astro-
cytes, oligodendrocytes and ependymal cells which are derived from the neu-
roepithilium forming the neuronal tube, microglial cells are of mesodermal origin 
(Chan et al., 2007; Pont-Lezica et al., 2011). 
In the healthy brain microglia are widely distributed throughout all regions and re-
side closely with neurons and astrocytes (Lawson et al., 1990; Nimmerjahn et al., 
2005; Tremblay et al., 2010; Wake et al., 2009). Microglia express receptors for all 
known neurotransmitters and are able to synthesise many neuroactive molecules 
(Kettenmann et al., 2011; Lucin and Wyss-Coray, 2009). 
Under healthy conditions microglia have a ramified/branched appearance with a 
small cell soma. Microglia with this appearance are also called resting microglia, 
which may be misleading as they are constantly and actively scanning the envi-
ronment within the CNS with their ramified processes (Nimmerjahn et al., 2005). 
Microglial cells have a very plastic phenotype and can change their morphological 
and functional spectrum depending on their so called state of activation (Figure 5). 
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Under certain conditions microglia have the capability to transform into macro-
phages but their functions differ from macrophages in other organs (Graeber and 
Streit, 2010). 
 
 
 
Figure 5: schematic illustration of the morphological change from resting ramified 
microglia towards activated microglia. Some elements of the figure were produced 
using Servier Medical Art (www.servier.com). 
 
Microglia are suggested to have several functional phenotypes. In the healthy brain 
microglial cells do not remain silent but show high dynamic motility. During devel-
opment neuronal synapses are being extensively formed, remodelled and a large 
number of immature synapses are again eliminated by a process called synaptic 
pruning (Hua and Smith, 2004). Recent in vivo imaging and high resolution EM 
studies have shown that microglia actively and transiently connect to dendritic 
spines in healthy mouse cortex (Tremblay et al., 2010; Wake et al., 2009). Therefore, 
microglia are suggested to monitor the functional status of synapses and thus the 
CNS circuitry (Tremblay et al., 2011). In the adult brain, microglia can detect dys-
functional synapses and are also involved in a phenomenon called postlesional syn-
aptic stripping. In this process, microglial cells remove branches from nerves near 
damaged tissue to promote neurogenesis and remapping of the CNS circuitry (Trapp 
et al., 2007). Also, under disease conditions and in the removal of myelin debris 
they serve as macrophages and antigen-presenting cells of the brain (Graeber, 2010).  
Further, microglia are suggested to play a role in neurotransmission and may act as 
an upstream partner for astrocytes (Pascual et al., 2012; Tremblay et al., 2011). It 
has been shown that activation of microglia involves ATP and the purinergic recep-
tor P2Y1 (Pascual et al., 2012). This receptor is only expressed in neurons and astro-
cytes. Microglial activation results in microglial ATP production, which in turn 
activates astrocytic ATP production and leads to a P2Y1 receptor mediated glutamate 
release (Pascual et al., 2012; Tremblay et al., 2011). Possible downstream effects 
might be glutamate binding to neuronal receptors (e.g. the metabotropic glutamate 
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receptor 5 (mGluR5)), which in turn then increases the excitatory postsynaptic cur-
rent frequency (Pascual et al., 2012; Tremblay et al., 2011). 
Microglia can be visualised in brain tissue and cell cultures. The number of markers 
for the identification of all microglial activation stages is still growing, but a mo-
lecular marker that does not also recognise peripheral macrophages remains un-
known. Anyhow, the markers are cell-type specific and do not label other glia cell 
types or neurons in the CNS. Griffonia simplicifolia isolectin B4 (ILB4) or tomato 
lectin has been proven to be useful in lectin-histochemical/antibody-based experi-
ments (Kettenmann et al., 2011). Blood vessels can be stained with this method as 
well but they can be easily distinguished by morphological criteria under the micro-
scope. Other established antibody markers for microglia are e.g. CD11b (CD18, 
complement receptor 3), IBA-1 (ionised calcium adaptor protein 1), CD45 (leuko-
cyte common antigen), CD68 (macrosialin), CD163 (scavenger receptor M130), 
CD169 (sialoadhesin, siglec-1), GLUT5 (glucose transporter 5) and F4/80 antigen 
(Kettenmann et al., 2011). The expression levels of some of the molecules correlate 
with the state of microglial activation e.g. IBA-1, CD11b and CD68. 
2.2.1.4 Astrocytes 
The most abundant cells in the mammalian brain are astrocytes, named after their 
stellate shape, which are involved in various processes in the CNS. Astrocytes ex-
press high amounts of intermediate filaments (if), which build the cytoskeleton. The 
glial fibrillary acidic protein (GFAP) and vimentin are the two main types of IF 
proteins in astrocytes (Verkhratsky and Butt, 2007). GFAP is used as marker to 
detect astrocytes. Its expression levels are especially increased in reactive astrocyto-
sis. Interestingly, in healthy adult mammals the GFAP expression varies within 
types of astrocyte as only 15-20% express it in the cortex and hippocampus, but 
almost all Bergmann glial cells in the cerebellum express GFAP (Verkhratsky and 
Butt, 2007). It has been shown that GFAP is not the best marker to study astrocyte 
morphology itself as it only stains the primary branches, which only represent about 
15% of the total volume of an astrocytic cell (Bushong et al., 2002). Remarkably, 
one astrocytic cell in rodents is capable to cover a spatial domain up to 80.000 μm3, 
wrap multiple neuronal somata, associate with up to 600 neuronal dendrites, and 
contact up to 100.000 individual synapses (Freeman, 2010). These numbers increase 
considerably in humans. The volume of one astrocyte is almost 30 times higher than 
in rodents and can contact about 2.000.000 synapses (Freeman, 2010). 
Classification of astrocytes is based on their morphology. The largest group, stellate-
shaped astrocytes, include protoplasmic (grey matter) and fibrous (white matter) 
astrocytes (Kimelberg, 2010; Verkhratsky and Butt, 2007). Another large group of 
astrocytes are radial glia, bipolar cells with elongated processes and an ovoid cell 
body. Radial glia are common in the developing brain and are the first cells gener-
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ated from neuronal progenitors. Later, this cell type disappears from many brain 
regions and converts to stellate-shaped astrocytes. In adults, radial glia are still pres-
ent in the retina (Müller glia) and cerebellum (Bergmann glia) (Reichenbach et al., 
2010). Furthermore, smaller populations of astrocytes have been described, being 
localised to specific brain regions, called vellate (cerebellum), interlaminar (primate 
cortex), tanycytes (periventricular organs, hypophysis, raphe part of the spinal cord), 
pituicytes (neurohypophyse), perivascular and marginal astrocytes (Verkhratsky and 
Butt, 2007). Moreover, astrocytes that surround the ventricles or the subretinal re-
gions are called ependymocytes, choroid plexus and retinal pigment epithelial cells 
(Verkhratsky and Butt, 2007). 
Astrocytes in general serve developmental functions such as neuronal path finding 
and regulation of synaptogenesis (Slezak and Pfrieger, 2003). They are substantial 
for the formation and regulation of the blood-brain barrier (BBB) (Koehler et al., 
2009) and provide various nutrient and metabolic substrates for neurons. Astrocytes 
also participate in the control of ion concentrations and the pH of the extracellular 
spaces in the CNS (Maragakis and Rothstein, 2006), and are important for synaptic 
function and neurotransmitter synthesis (Perea et al., 2009). They contain processes 
with end-feet which contact the brain vasculature and cover neuronal synapses and 
hence play a central role in modulating neuronal activity and the cerebral blood 
flow. Additionally, the cells are excitable, which is detectable by increased Ca2+ 
concentrations in the cytosol due to mobilisation of Ca2+ from the ER. The increased 
Ca2+ level can create a signal which can occur spontaneously in the absence of neu-
ronal activity or be induced by neurotransmitters (Perea and Araque, 2005). The 
manifold functions of these extraordinary cells make it clear that dysfunctions of 
these cells can lead to drastic consequences.  
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2.2.2 Pathophysiology of neurons and glia in neurodegeneration 
Neurodegeneration is characterised by progressive loss of neuron structure and func-
tion. This can be caused by defects in neurons themselves or can be a secondary 
effect due to dysfunctional glial cells. CNS insults lead to specific reactions of glial 
cells, known as reactive gliosis. These reactions include activation of microglia, 
reactive astrocytosis, and disturbed oligodendrocyte biology which are all funda-
mental in the progression of neural pathology. 
??????? ??????????????????
The hallmark of neurodegenerative diseases is the progressive loss of neurons. In 
most cases there is no cure, only symptoms can be treated to provide partial relief 
for the patients. Treatment of patients is often delayed due to the fact that many cells 
are already dead before symptoms occur. Neuronal activity can be disrupted at many 
stages: molecular pathways can be interrupted (Bossy-Wetzel et al., 2004), synapses 
can be affected (Shankar and Walsh, 2009), neuronal subpopulations and local cir-
cuits in certain brain regions or even higher order neuronal networks can be dam-
aged (Palop et al., 2006). 
Neurodegenerative diseases are often associated with intracellular and/or extracellu-
lar accumulation of misfolded proteins, like Creutzfeldt-Jacob, Parkinson’s and 
Alzheimer’s diseases (PD and AD). However, the underlying mechanisms why neu-
rons die and the early steps of the disease are complex and poorly understood (Na-
kamura and Lipton, 2009). For instance, in PD patients accumulations of α-
synuclein and synphilin aggregates are found, called Lewy bodies. In the brain of 
AD patients intracellular neurofibrillary tangles, containing hyperphosphorylated 
tau, and extracellular β-amyloid plaques are found (Nakamura and Lipton, 2009). 
Misfolded proteins cause continuous ER-stress, continued by disturbances in the 
protein folding and clearance machinery (Mukherjee et al., 2011). ER-stress leads to 
the activation of the unfolded protein response (UPR). The purpose of UPR is the 
restoration of ER function. In order to achieve this, global protein synthesis is shut 
down to reduce the load and proteins that are important for the degradation of mis-
folded proteins (mutant/unfolded) are upregulated. However, if the ER function is 
too severely affected, cell death pathways are activated. ER-stress also leads to dis-
ruption of calcium homeostasis (Mukherjee et al., 2011). This is deleterious espe-
cially for neurons as calcium is important in neuronal activity. Ca2+ acts as second 
messenger in various signaling pathways and is stored in the ER. Intracellular gradi-
ents are normally maintained by Ca2+ channels and ATP-driven Ca2+ pumps. In 
neurodegenerative diseases increased levels of Ca2+ in the cytoplasm have been re-
ported, leading to disturbed intracellular signalling (Mukherjee et al., 2011).  
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To study basic mechanisms of neurodegeneration inherited monogenetic neurode-
generative disorders can serve as helpful models as the defective gene is usually 
known and subsequent pathways which lead to neurodegeneration can be analysed 
in detail. 
??????? ??????????????????????????
Oligodendrocytes are responsible for the myelination integrity and function of neu-
rons. Disturbances in oligodendrocyte biology are associated with major diseases of 
the CNS and often have an impact on white matter structures. CNS white matter can 
be affected in many ways e.g. by disturbed myelination, loss of the myelin sheaths, 
gliosis, axonal damage which in turn has an impact on the myelin integrity or by 
permanent myelin deficiency. Some diseases with myelin defects due to mutations 
in myelin proteins are muscular dystrophies, mitochondrial or peroxisomal diseases, 
and many more.  
Multiple sclerosis (MS) is an example for an immune-mediated demyelinating dis-
ease. The trigger and primary cause of MS remains elusive. Genetic predisposition 
and environmental factors are suggested to be involved in the disease (Compston 
and Coles, 2008). Genetic involvement has been shown due to the high disease con-
cordance in monozygotic twins (Handunnetthi et al., 2010). However, it is not a 
single gene defect which leads to the disease. Involvement of environmental factors 
is supported due to the fact that MS is more frequent in northern than in southern 
regions in the world (Compston and Coles, 2008). In MS, lymphocytes and mono-
cytes cross the blood-brain-barrier (BBB), and oligodendrocytes/myelin sheaths are 
destroyed due to inflammation, but interestingly rarely neurons directly (Nave, 
2008). Another example where myelination is affected are leukodystrophies, a group 
of rare inherited dys-/demyelination diseases (Nave, 2008). In this case oligodendro-
cytes are incapable to correctly assemble or maintain myelin and these patients usu-
ally suffer from a severe delay in motor and cognitive development. 
??????? ??????????????????????
Microglia serve protective and pathogenic functions. The recent view on microglia 
in disease suggests rather an active protective than an aggressive role (Graeber and 
Streit, 2010). Nevertheless, it is currently not clear how much chronic forms of in-
flammation contribute to the pathogenesis in neurodegenerative diseases in general 
(Saijo and Glass, 2011). Microglia respond to inflammatory or injurious stimuli in 
the CNS in a pre-programmed manner that is designed to kill and to set the stage for 
repair and resolution of the disease. Activated microglia can be distinguished by 
combined immunophenotypic and morphological changes. They produce many pro-
inflammatory mediators like reactive oxygen species (ROS), cytokines and 
chemokines, which are involved in the pathogen clearance (Saijo and Glass, 2011). 
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On the other hand, prolonged and excessive microglial activation can lead to patho-
logical inflammation that may contribute to neurodegenerative diseases (Glass et al., 
2010; Perry et al., 2010). Microglia are suggested to take part in the adaptive im-
munity by expressing MHC class II (major histocompatibility) in the active state, 
which in turn activates native T cells to differentiate into effector T cells but in vivo 
this hypothesis has not been proven yet (Saijo and Glass, 2011). 
??????? ??????????????????????
All kinds of brain insults cause a complex astroglial response, which can be ob-
served as astrocyte hypertrophy and proliferation. This is a defensive brain reaction 
with the goal to isolate the damaged area from the rest of the tissue, to rebuild the 
BBB and to help to remodel brain circuits surrounding the damaged areas. Hall-
marks of reactive astrocytes are hypertrophy and a significant increase in the cy-
toskeleton production: the protein synthesis of intermediate filaments such as GFAP 
and vimentin is highly upregulated. GFAP and vimentin form the cytoskeleton to-
gether with actin and microtubules. It has also been reported that the crosstalk be-
tween activated microglia and astrocytes can amplify inflammatory responses and 
contribute to the release of neurotoxic factors (Saijo and Glass, 2011). Epilepsies are 
a group of disorders which are characterised by periodic seizures. Astrocytes are 
suggested to play a role in seizure generation and spread within the CNS as these 
cells are involved in the control of neuronal firing (Seifert et al., 2010; Seifert and 
Steinhauser, 2011). In principal, a neuron operates by receiving signals from other 
neurons via its synapses. The combination of the incoming signals leads to an excess 
of a threshold, which in turn results in so called neuronal firing, meaning that the 
neuron is sending further signals to connective neurons. These signals can be either 
excitatory or inhibitory to a neuron. Astrocytes express transporters that take up 
glutamate to terminate the action of this neurotransmitter at synapses in the CNS 
(Seifert et al., 2010). Changes in the activity of these transporters have been shown 
to be characteristic in temporal lobe epilepsy (TLE) and other brain disorders 
(Seifert et al., 2010). Further, excessive extracellular glutamate has been detected in 
human epileptogenic tissue and was reported to stimulate recurrent seizures and 
neuronal cell death (Seifert et al., 2010). Astrocytes are involved in the integrity. 
Therefore, it is logical that defects in the BBB has been suggested to play a role in 
seizure generation (Seifert et al., 2010). 
Although little is understood about the interplay and molecular pathways between 
neurons and glia in disease, it becomes more and more apparent that glial activation 
is not always bad. Astrocytes and microglia are important for the environmental 
homeostasis of neurons, clearance of debris and in general fulfil rather neuroprotec-
tive than destructive roles in the CNS. 
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2.3 Lipid metabolism 
2.3.1 Cholesterol homeostasis and transport 
Cholesterol and phospholipids are essential components of mammalian membranes. 
In mouse and human about one quarter of the total amount of cholesterol is found in 
the CNS. Mammals are able to absorb lipids via food intake but as basically every 
cell is also capable to synthesise cholesterol de novo from acetyl-CoA (AcCoA) this 
is not necessarily required (Dietschy, 2009) (Figure 6). Cholesterol transport is a 
highly regulated process. Cholesterol from food intake is absorbed in the intestinal 
lumen at the microvillus border via Niemann Pick type C like protein (NPC1L1) 
into the cytosolic compartment (Dietschy, 2009) (Figure 6). It is then esterified into 
cholesteryl ester (CE) and associated with chylomicron particles. Systemic tissues 
can produce cholesterol de novo and take up lipids from plasma lipoprotein com-
plexes, chylomicrons, low-density or very-low-density lipoproteins (LDL, VLDL) 
(Figure 6). These complexes transport lipids from one organ to another and conse-
quently provide peripheral cells with membrane components and precursors to gen-
erate steroids. High density lipoprotein (HDL) is important for reverse cholesterol 
transport from peripheral tissues to the liver since the liver is the only organ actively 
excreting cholesterol (Figure 6). In general, lipoprotein particles consist of triacyl-
glycerols, unesterified and esterified cholesterol, phospholipids and apolipoproteins 
and their density decreases the more neutral lipids they contain. Lipoprotein parti-
cles in the blood are spherical and among the major structural apo lipoproteins 
apoA-I is linked to HDL, apoB-100 to LDL and VLDL and apoE to HDL and 
VLDL (Mahley et al., 1984). 
Liver and other tissues express the low density lipoprotein receptor (LDLR), which 
plays a key role in receptor-mediated endocytosis of cholesterol and CE that are 
associated with lipoproteins containing apoB-100 or apoE (Figure 6). Further, liver 
and endocrine glands are the main tissues expressing the transporter scavenger re-
ceptor class B type I (SR-BI). SR-BI selectively facilitates the uptake of CE from 
HDL into the cytosolic cell compartments (Figure 6). Also, LDL can bind to the 
SR-BI receptor in adrenocortical glands where corticoid biosynthesis takes place. 
Cholesterol and CE that were taken up via the LDLR or bulk-phase endocytosis pass 
through the late endosomal/lysosomal compartment of cells and sterols incorporated 
via SR-BI and NPC1L1 are moved directly into the metabolically active pool in the 
cytosol (Liu et al., 2007; Xie et al., 2000) (Figure 6). Niemann Pick type C1 (NPC1) 
is another sterol transporter which acts together with Niemann Pick type C2 (NPC2). 
CEs are hydrolysed in late endosomes/lysosomes by an enzyme called lysosomal 
acid lipase (LAL) and free cholesterol is transferred to NPC2, and further to NPC1. 
Cholesterol is transported to the luminal leaflet of the vesicles, flips to the cytosolic 
side and can be transported by cytosolic carriers to other destinations (Kwon et al., 
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2009). Further, NPC1 plays a role in transporting cholesterol from the late 
endosomal/lysosomal compartment to the cytosolic metabolic active pool (Dietschy, 
2009) (Figure 6). The metabolically active pool in the cytosol supports continuous 
turnover of cholesterol in the plasma membrane (Aqul et al., 2011) (Figure 6). Leci-
thin:cholesterol acyltransferase (LCAT) in circulation is involved in the cholesterol 
conversion to CE and is essential for the formation of spherical HDL. Also in the 
brain LCAT is present, though at lower concentrations and is mainly expressed by 
astrocytes (Hirsch-Reinshagen et al., 2009). 
ABC (ATP-binding cassette) transporters are involved in the transport of lipids to 
the cell surface and facilitate further lipidation of HDL particles and subsequent 
reverse cholesterol transport (RCT) to the liver. These include especially ABCA1 
and ABCG1 and 4 (van der Velde, 2010). Excessive cholesterol is either directly 
excreted in the feces or first converted to bile acids and subsequently excreted (Diet-
schy, 2009) (Figure 6). Reverse cholesterol transport from peripheral cells and the 
CNS to the liver for excretion or bile acid synthesis is mediated via circulating HDL 
(Ikonen, 2008). 
In the CNS, lipids fulfil a wide range of physiological functions such as myelination, 
neurite outgrowth (Vance et al., 2005), synaptogenesis (Slezak and Pfrieger, 2003) 
and can act as signalling molecules (Bazan, 2003). The unique composition of the 
brain and relative isolation from the rest of the body system affect the lipid compo-
sition in the CNS, which differs from the rest of the body. One difference is the 
distribution of cholesterol in the brain, where most of it is located in myelin formed 
by oligodendrocytes. Interestingly, cholesterol uptake across the blood-brain barrier 
(BBB) is not detectable neither in newborn nor adult rodents or humans and there-
fore the plasma cholesterol supplies are blocked by the BBB (Hayashi, 2011). 
Hence, high rates of de novo cholesterol synthesis in neurons and glial cells e.g. 
astrocytes provide the essential amounts of cholesterol during development. The 
rates of cholesterol synthesis are in line with myelin production, being highest dur-
ing the first four weeks after birth in mice (Hayashi, 2011). Oligodendrocytes pro-
duce the myelin sheaths, which are rich in cholesterol, galactosphingolipids and 
saturated long-chain fatty acids. Surrounding the axons with these thick hydrophobic 
membranes increases the velocity of electrical conduction along neurons (Dietschy 
and Turley, 2004). In adult rodents and humans the cholesterol synthesis still con-
tinues, but at lower rates (Dietschy, 2009). After the myelination process of oligo-
dendrocytes, astrocytes are the key players for cholesterol synthesis and supply for 
neurons (Hayashi, 2011) (Figure 6). Neurons do not synthesise sufficient amounts 
of cholesterol and depend on external supply by e.g. astrocytes (Nieweg et al., 
2009). 
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In the brain the main lipoprotein particles are called HDL-like particles and are disc-
oidal and smaller than in plasma (Koch et al., 2001; Legleiter et al., 2004). Several 
of the proteins involved in cholesterol transport in the circulation are also present in 
the cerebrospinal fluid (CSF) of the CNS. The major CNS apolipoprotein is apoE 
and plays the central role in lipid metabolism in the brain with a concentration of 5-
15% of that in plasma (Hayashi, 2011). Other apo lipoproteins such as apoA-I, A-II, 
CI-III, D and J are also present in the CSF (Hayashi, 2011). It has been shown that 
mouse primary astrocyte cultures secrete apoE, J and D but not apoA-I (DeMattos et 
al., 2001). ApoA-I, the major HDL apolipoprotein in the blood is not synthesised in 
the brain and thought to be either able to cross the BBB (Kratzer et al., 2007) or may 
be synthesised by capillary endothelial cells (Panzenboeck et al., 2002). 
Under normal conditions, HDL-like particles are secreted mostly from astrocytes 
and microglia, and can be secreted from neurons under certain conditions (Hayashi, 
2011). For example, apoE synthesis is known to take place in astrocytes (Pitas et al., 
1987), microglia (Nakai et al., 1996) and at low levels in neurons (Brecht et al., 
2004). Glial cells secrete apoE, phospholipids and cholesterol which form HDL-like 
particles. These particles can then bind to apoE receptors on neurons (Figure 6). 
Neurons express several members of lipoprotein receptors from the large class of the 
LDL receptor superfamily (LDLR), which bind to apoE and are involved in choles-
terol transport amongst other functions (Hayashi, 2011; Vance and Hayashi, 2010) 
(Figure 6). Neurons have been reported to express the LDL receptor, the LDL re-
ceptor related (LRP1), the VLDL receptor and the apoE receptor-2 (apoER2). Many 
are also expressed in microglia, astrocytes and oligodendrocytes (Vance and Haya-
shi, 2010). 
In the CNS the ABC transporters are key players in the transport of lipids to the cell 
surface and facilitate the lipidation to lipoparticles, especially ABCA1, ABCA2, 
ABCG1 and ABCG4 (Kim et al., 2008). The plasma membrane ABCA1 transporter 
is important for the phospholipid and cholesterol efflux from neurons to apoE. The 
endo/lysosomal ABCA2 mediates intracellular sphingolipid transport and myelin 
maturation and is highly expressed in oligodendrocytes. The vesicular ABCG1/4 
transporters mediate intracellular cholesterol transport and efflux in neurons and 
astrocytes. ABCG1 is also highly expressed in microglia (Kim et al., 2008). The 
sterol synthesis is balanced by metabolising excessive cholesterol to 24(S)-
hydroxycholesterol, which is able to cross the BBB and thereby is eliminated from 
the CNS (Lutjohann et al., 1996) (Figure 6). 
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Figure 6: simplified scheme of the cholesterol flow through the major tissue com-
partments. The body is divided into four tissue compartments intestine, liver, central 
nervous system (CNS) and remaining peripheral tissues. The thick black arrows repre-
sent the cholesterol flow through plasma carried in CM, VLDL/LDL and HDL. The 
specific cholesterol transporters LDLR (white), NPC1 (dark grey), ABCA1 (black), SR-
BI (light grey), and NPC1L1 (grey) are shown. Two intracellular cholesterol pools are 
indicated within each compartment: one is located in the late endosomal/lysosomal com-
partment (solid circle) and the other is the metabolically active pool of unesterified cho-
lesterol in the membranes of the cytosolic compartment (dashed circle). Cholesterol 
transport from the lysosomal to the metabolically active pool requires NPC1. NPC2 (not 
shown), acts together with NPC1 to promote cholesterol flow out of the lysosome. ApoE 
is expressed in astrocytes and assembled with unesterified cholesterol (C) in order to 
build apoE lipoproteins (apoE-C). ApoE-C binds to receptors on the cell surface of neu-
rons. In the CNS, excessive cholesterol is oxidised to 24-hydroxycholesterol (24-OH 
chol). 24-OH chol is then transported via the blood-brain-barrier (BBB) and blood 
plasma to the liver, where it is excreted into bile for elimination. Abbreviations: Ac-
CoA, Acetyl-CoA; BBB, blood brain barrier; BD, bile duct; C, unesterified cholesterol; 
CE, cholesteryl ester; BA, bile acid; 24-OH-C, hydroxylated cholesterol. Modified from 
Dietschy, 2009. 
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2.3.2 Sphingolipid metabolism 
Sphingolipids present essential components of cell membranes and comprise a large 
family of glycolipids and phospholipids sharing a sphingoid base backbone. Synthe-
sis takes place in the ER and Golgi compartment and the sphingolipids can be sub-
sequently delivered to the plasma membrane (Chatterjee, 1998; Simons and Vaz, 
2004). Ceramide is a component of most sphingolipids and acts as an anchor for 
lipid-bound carbohydrates (Kolter and Sandhoff, 1999). Sphingolipids that do not 
contain carbohydrate residues also exist, like ceramide itself, sphingomyelin or 
sphingolipid metabolism intermediates such as sphingosine (Young et al., 2012). 
Lactosylceramide is the common precursor of various glycosphingolipids (GSLs) 
and synthesised by the enzyme galactosyltransferase I, which transfers a galactose 
moiety from UDPgalactose to glucosylceramide (Kolter and Sandhoff, 1999). Sugar 
residues are added stepwise in the Golgi compartment by membrane bound glyco-
syltransferases (Kolter and Sandhoff, 1999). In the plasma membrane, sphingolipids, 
especially sphingomyelin, are suggested to concentrate in pre-existing microdo-
mains called lipid rafts (Kolter and Sandhoff, 2006). Lipid rafts are reported to con-
tain higher levels of glycosylphosphatidylinositol-anchored proteins, sphingomyelin, 
and cholesterol (Kolter and Sandhoff, 2006). Further, cholesterol/sterols and sphin-
golipids have been reported to interact and to be co-regulated (Mukherjee and Max-
field, 2004; Puri et al., 2003). Sphingolipids have been shown to play a role in a 
wide range of functions like in cell recognition, apoptosis, cell growth, proliferation, 
inflammation, autophagy and differentiation (Bartke and Hannun, 2009). 
2.3.3 Cholesterol and sphingolipids in neurodegeneration 
The brain consists of ~2% cholesterol that is mainly generated via de novo synthesis 
(Zipp et al., 2007). Hence, factors affecting cholesterol metabolism could have a 
significant impact on CNS function. Defective cholesterol metabolism has been 
linked to several neurological disorders e.g. AD, NPC disease and NCLs (the latter 
to be discussed later in more details). ApoJ and apoE isoforms, particularly APOε4 
allele, have been connected to AD as genetic risk factors, but the underlying mecha-
nisms triggering the disease have not been clarified (Vance and Hayashi, 2010). 
Extracellular β-amyloid plaques and intracellular neurofibrillary tangles are charac-
teristic for AD. ApoE has been shown to co-localise with these hallmarks in AD 
patients (Namba et al., 1991). Recently, a study has shown that induced expression 
of apoE increased the clearance of β-amyloid plaques in AD mouse models (Cramer 
et al., 2012). Another example, where cholesterol trafficking is affected, is NPC 
disease belonging to the group of lysosomal storage disorders. Mutations in either 
NPC1 or NPC2 cause accumulation of the lipids cholesterol, sphingomyelin (SM), 
multiple GSLs and the catabolic product of sphingolipids sphingosine in lysosomal 
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storage compartments (Lloyd-Evans et al., 2008). NPC1 and NPC2 are involved in 
cholesterol efflux from late endosomes/lysosomes (Rosenbaum and Maxfield, 2011) 
(see 2.3.1). Sphingolipidoses comprise a group of inherited diseases and belong to 
the LSDs (see 2.1.4), caused by defects in genes encoding proteins involved in the 
lysosomal degradation of sphingolipids. The degradation pathway of glycosphin-
golipids in humans is strictly sequential and defects for nearly every step have been 
reported except for the degradation of lactosylceramide (Kolter and Sandhoff, 2006). 
Lactosylceramide can be degraded by two different enzyme/activator systems and 
no single enzyme defect has been described to cause isolated lactosylceramide stor-
age (Zschoche et al., 1994). However, in combination with other sphingolipids, 
lactosylceramide accumulates when various cofactors are absent, as e.g. in pros-
aposin deficiency (Kolter and Sandhoff, 2006). 
2.4 Neuronal Ceroid Lipofuscinoses (NCL) 
2.4.1 Common clinical and pathological features 
Neuronal ceroid lipofuscinosis (NCL) is a collective term for a group of rare and 
severe autosomal recessive inherited diseases belonging to the superior group of 
lysosomal storage disorders. In Finland the number of new NCL diagnoses is 2-3 per 
year and the estimated NCL incidence per 100.000 live births is 4.82 (Mole et al., 
2011). The estimated prevalence per million population is 9.4 (Mole et al., 2011). 
Hallmarks of NCLs are degeneration of the brain and often the retina, the accumula-
tion of autofluorescent lipofuscin-like lipopigments in the lysosomes of neuronal 
and extraneuronal tissues (Goebel, 1997). NCLs are considered to be the most com-
mon neurodegenerative disorders of childhood. Patients are found worldwide and so 
far almost 365 mutations causing NCLs have been described occurring in 9 genes, 
CLN1, CLN2, CLN3, CLN4, CLN5, CLN6, CLN7, CLN8 and CLN10 (NCL mutation 
data base, http://www.ucl.ac.uk/ncl) (Kousi et al., 2012). The age of onset in NCLs 
varies from newborn to adult, but clinical features are quite similar to each other, 
including motor disturbances, progressive blindness, epilepsy and eventually prema-
ture death (Haltia, 2003; Jalanko and Braulke, 2009).  
The storage materials in cells of NCL patients show various ultrastructures that cor-
relate with the underlying mutated gene and type of NCL. The shape of the ultra-
structures can vary from granular osmiophilic deposits (GRODs) to fingerprint (FP), 
curvilinear (CL) or rectilinear (RL) profiles (Elleder et al., 1999). An overview of 
the classic clinical phenotypes and their variations associated with the NCL genes, 
the major components of the storage material and ultrastructural phenotype, are 
presented in Table 1. However, the storage material in NCL patients is not con-
sidered to be disease-specific and consists mostly of sphingolipid activator proteins, 
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also known as saposins A and D (SAPs A and D) or the subunit c of the mitochon-
drial ATP synthase (Mole et al., 2011). 
To date, NCLs are divided into ten forms according to the mutated genes CLN1 to 
CLN10, even though not all genes have been identified (Table 1). Originally, the 
classification was based on clinical and phenotypical characteristics. Different muta-
tions within one gene may result in varying phenotypes and age of onset, which 
makes diagnosis complicated on the basis of clinical or phenotypical features. Re-
cently, a new nomenclature system has been proposed, which includes the NCL 
subtypes (Kousi et al., 2012). This intends to provide better understanding for clin-
icians, scientists, patients and affected families. The new system derives from the 
genetic defect and takes the varying phenotype into account, e.g. CLN5 disease, late 
infantile variant (Kousi et al., 2012). 
2.4.2 NCLs and disturbed lipid metabolism 
Several NCLs have been linked to disturbed lipid metabolism. Human patients of 
CLN1 and CLN3 diseases display abnormal molecular phospholipid species in cere-
bral cortex measured by normal phase high performance liquid chromatography 
(HPLC) and on-line electrospray ionisation ion-trap mass spectrometric detection 
(LC–ESI–MS) (Käkelä et al., 2003). Further, 1 month old Cln1 ko mice have been 
shown to present reduced levels of total cholesterol and apoA-I and attenuated phos-
pholipid transfer protein (PLTP) activity in serum lipid analyses (Lyly et al., 2008). 
PLTP has been shown to be involved in the transfer process of cholesterol to HDL 
through the ABCA1-mediated pathway (Oram et al., 2003). 
Two NCL proteins, the palmitoyl protein thioesterase (PPT1/CLN1) and CLN5 have 
been shown to interact in in vitro pulldown assays with the mitochondrial F1-ATP 
synthase (Lyly et al., 2008; Lyly et al., 2009). The mitochondrial F1-ATP synthase 
has been reported to act as a receptor for apoA-I (Martinez et al., 2003). The ectopic 
α- and β-subunits of the ATP synthase were found to be enriched at the plasma 
membrane in Cln1 ko neurons by total internal reflection fluorescence (TIRF) mi-
croscopy and radiolabelled apoA-I uptake was increased in Cln1 ko glial cells and 
neurons (Lyly et al., 2008). CLN8 contains domains which are suggested to play 
roles in ceramide synthesis, lipid regulation and protein translocation in the ER 
(Winter and Ponting, 2002). Further, NCL disease models, as for Cln6 and Cln10 
(Cathepsin D knockout), have been shown to contain increased amounts of complex 
glycosphingolipids (Jabs et al., 2008). Finally, CLN10/Cathepsin D has been sug-
gested to regulate ABCA1-mediated phospholipid and cholesterol efflux (Haidar et 
al., 2006).  
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2.4.3 Common pathways behind NCLs 
Originally, Zhong and co-workers hypothesised that NCL proteins do not interact 
with each other, based on yeast two–hybrid studies between PPT1, 2 and 3 (Zhong 
et al., 2000). A few years later protein-protein interactions among NCL proteins 
have been described by in vitro experiments using co-immunoprecipitation, GST-
pulldown assays and by an experiment, which showed that defective cell growth of 
patient cell lines could be reversed by transfecting NCL proteins (Lyly et al., 2009; 
Persaud-Sawin et al., 2007; Vesa et al., 2002). Lyly et al. suggested that CLN5 
interacts with most of the other NCL proteins like PPT1/CLN1, TPP1/CLN2, CLN3, 
CLN6 and CLN8 (CLN7 and CLN10/Cathepsin D have not been tested). The other 
NCL proteins are also suggested to interact with each other. On gene level common 
pathways have been suggested for Cln1 and Cln5 by comparative gene array studies 
on knockout mouse brains (von Schantz et al., 2008). The F1-ATPase has been 
shown to bind to both, PPT1/CLN1 and CLN5, in GST pulldown assays (Lyly et al., 
2009). Figure 7 summarises the suggested NCL protein-protein interactions. 
 
 
 
Figure 7: scheme of NCL protein-protein interactions in vitro. Proteins are repre-
sented in the cellular compartment in which they are localised. Arrows with continuous 
lines indicate reported CLN5 interactions (Lyly et al., 2009; Vesa et al., 2002; von 
Schantz et al., 2008). Dashed arrows indicate other suggested protein-protein interac-
tions within the NCL proteins (Persaud-Sawin et al., 2007). 
Abbreviations: CLN, ceroid lipofuscinosis, neuronal; ER, endoplasmic reticulum; 
PPT1, palmitoyl protein thioesterase 1; TPP1, tripeptidyl peptidase 1. Some elements of 
the figure were produced using Servier Medical Art (www.servier.com). 
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2.4.4 CLN5 disease, late infantile variant NCL 
Originally, CLN5 disease, late infantile variant phenotype was thought to be con-
fined to Finland, and therefore was known as Finnish variant late infantile NCL 
(vLINCLFin). The prevalence of CLN5 disease in Finland is 2.6 per million inhabit-
ants but even higher in the Southern Ostrobothnia area with a prevalence of 1:5000 
within the local child population of 15 years of age or younger (Uvebrant and Hag-
berg, 1997). Within the last couple of years it has become more and more evident 
that CLN5 disease is not confined to the Finnish population but found all over the 
world in a variety of different ethnic groups (Bessa et al., 2006; Cannelli et al., 2007; 
Cismondi et al., 2008; Holmberg et al., 2000; Kousi et al., 2009; Lebrun et al., 2009; 
Pineda-Trujillo et al., 2005; Sleat et al., 2009; Xin et al., 2010; and unpublished). 
Patients have been found in Europe (Italy, Portugal, Sweden, the Czech Republic, 
the Netherlands, UK), in North (USA, Canada) and South (Argentina, Columbia) 
America and many other countries such as Afghanistan, China, Egypt or Pakistan or 
with Arabian, Asian or Hispanic origin (NCL mutation data base, 
http://www.ucl.ac.uk/ncl).  
The majority of patients carry a 2.0-bp deletion of the CLN5 coding region at the 
end of the sequence which leads to an early stop codon in CLN5 protein sequence 
(Holmberg et al., 2000; Savukoski et al., 1998). In addition 27 mutations and 9 
polymorphisms have been characterised (NCL Mutation Database: 
http://www.ucl.ac.uk/ncl). 
First clinical symptoms of CLN5 disease include motor disturbances and loss of 
vision usually at the age 4-7 years (Holmberg et al., 2000; Santavuori et al., 1991; 
Santavuori et al., 1982; Xin et al., 2010). The disease progresses with motor and 
mental deterioration, myoclonia, seizures and ultimately leads to death in most cases 
at the age of 12-23 years of age. However, two adult onset patients have been re-
ported with a delay of 6 to 8 years between the onset of the disease and disease pro-
gression (Xin et al., 2010).  
Neuropathological features are generalised cerebral and extreme cerebellar atrophy 
(Autti et al., 1992; Tyynelä et al., 1997). In the late stage of disease, Purkinje cells 
in the cerebellum and thalamic neurons are almost completely lost, and cortical neu-
rons, often in a laminar pattern involving laminae III and V, are mildly to moder-
ately obliterated, but present moderate to pronounced enlargement of cells, called 
ballooning (Tyynelä et al., 1997). White matter edema (spongiosis) may be also 
observed (Cannelli et al., 2007). Widespread extensive astrocytosis in the cortex and 
cerebellum has been reported in patients and Cln5-/- mice (Tyynelä et al., 2004; von 
Schantz et al., 2009). Moreover, mild microglial activation in patients has been 
shown by the marker CD68, presenting enlarged cells with autofluorescent material 
(Tyynelä et al., 2004). In addition, myelin loss is a clinical feature in patients (Autti 
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et al., 1997). The storage material mainly consists of the subunit c of the mitochon-
drial ATP synthase, but also small amounts of SAPs A and D have been detected 
(Tyynelä et al., 1997). The ultrastructure of the cytoplasmic inclusion storage bodies 
can range from FP, CL to RL profiles (Tyynelä et al., 1997). 
CLN5 shows no homology to other proteins making it impossible to deduce its func-
tion from known proteins with comparable structures. The gene is only conserved in 
vertebrates. CLN5 consists of 407 aa with a predicted size of about 46 kDa (Sa-
vukoski et al., 1998). In contrast to other vertebrates, CLN5 in humans contains four 
possible initiator methionines. Consequently, the synthesis of wt CLN5 in a cell-free 
system resulted in four CLN5 proteins ranging from 39-47 kDa (Isosomppi et al., 
2002). The CLN5 protein contains eight predicted N-glycosylation sites and is 
highly glycosylated with high mannose and complex-type sugars leading to higher 
observed molecular weights in Western Blot analysis ranging from 52-75 kDa (Iso-
somppi et al., 2002; Vesa et al., 2002). Moreover, CLN5 contains three M6P moi-
eties connected to Asn320/330/401, pinpointing that CLN5 is a soluble lysosomal 
protein (Sleat et al., 2006). Prior to this study, the localisation and solubility of the 
CLN5 protein was debated (Bessa et al., 2006; Isosomppi et al., 2002; Savukoski et 
al., 1998; Vesa et al., 2002). Overexpression experiments have presented both ER 
(Vesa et al., 2002) and lysosomal localisation for CLN5 (Isosomppi et al., 2002; 
Vesa et al., 2002). Mouse Cln5 has been shown to be a soluble, lysosomal protein 
by immunofluorescence studies and a triton X-114 phase separation assay of transi-
ently transfected COS-1 cells (Holmberg et al., 2004). 
2.4.5 CLN1 disease, classic infantile NCL 
CLN1 disease, classic infantile NCL (formerly known as infantile NCL (INCL) or 
Santavuori-Haltia disease) is caused by mutations in the CLN1 gene, which encodes 
for a lysosomal enzyme, the palmitoyl protein thioesterase 1 (CLN1/PPT1) (Hellsten 
et al., 1996; Lehtovirta et al., 2001; Salonen et al., 2001; Vesa et al., 1995). PPT1 
cleaves palmitate from H-ras in vitro (Camp and Hofmann, 1993) but in vivo sub-
states remain elusive. The patients develop symptoms typically by the age of 6-12 
months and then progressively suffer from mental, cognitive and motor decline, 
severe microcephaly, myoclonus and loss of vision (Haltia et al., 1973b; Santavuori 
et al., 1973). By the age of 3 years the electroencephalogram (EEG) becomes usu-
ally iso electric, indicating a complete lack of brain activity. Death occurs early 
around 9-13 years of age (Santavuori, 1988). The storage material mainly consists of 
SAPs A and D (Tyynelä et al., 1993). The ultrastructures of the cytosolic inclusion 
bodies are granular osmiophilic deposits (GRODs) (Haltia et al., 1973a; Haltia et al., 
1973b). 
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To date, 48 mutations have been defined in CLN1 gene (NCL mutation data base, 
http://www.ucl.ac.uk/ncl). CLN1/PPT1 consists of 306 aa, has an N-terminal signal 
sequence of 26 aa, which is co-translationally cleaved, and has three Asn linked 
glycosylation sites, which are endoH sensitive (Bellizzi et al., 2000). CLN1/PPT1 
has been shown to use the MPR-dependent route to lysosomes (Hellsten et al., 1996; 
Sleat et al., 2005; Verkruyse and Hofmann, 1996).  
2.4.6 Cln1 and Cln5 animal models 
Animal model systems are invaluable tools to gain new insights into the molecular 
mechanisms underlying NCLs. NCLs are not restricted to humans and also occur in 
other vertebrates such as e.g. cattle, sheep, dog and mouse (NCL mutation data base, 
http://www.ucl.ac.uk/ncl). Small vertebrate models, like e.g. mouse and zebrafish, 
are useful animal models to investigate the mechanisms underlying this devastating 
disease and they are known to contain orthologues of NCL genes. In this thesis pro-
ject NCL mouse models lacking the Cln1, the Cln5 or both genes have been used.  
Two Cln1 knockout mouse models have been generated using different targeting 
strategies, leading to the deletion of exon 4 (Ppt1Δex4) or exon 9 (Cln1-/-) (Gupta et 
al., 2001; Jalanko et al., 2005). Both knockout mouse models present a severe infan-
tile NCL phenotype including profound brain atrophy, localised reactive gliosis and 
neurodegeneration. The defects are first detected in the thalamus and subsequently 
in the cortex (Bible et al., 2004; Kielar et al., 2007). Astrocytosis is first observed in 
individual thalamic nuclei, cortical laminae and cerebellum before the onset of neu-
ronal loss (Kielar et al., 2007; Macauley et al., 2009). Ppt1Δex4 mice have also been 
linked to disturbed lipid metabolism (Lyly et al., 2008). 
A knockout mouse model for Cln5 disease has also been generated by targeted dele-
tion of exon 3 of the Cln5 gene (Cln5-/-) (Kopra et al., 2004). Naturally occurring 
defects in Cln5 have been found in cattle, canine and sheep (Frugier et al., 2008; 
Houweling et al., 2006; Melville et al., 2005). Cln5-/- mice display a relatively slow 
disease progression with disturbed vision from 5 months onwards and relatively 
mild brain atrophy even in old mice (Kopra et al., 2004). Progressive loss of neurons 
within the thalamocortical system with a different timing compared to other NCL 
mouse models has been recently shown in Cln5-/- mice (von Schantz et al., 2009). 
Neuron loss in these mice occurs first in the cortex and subsequently in thalamic 
relay nuclei. To date, no therapeutic attempts have been made on these mice. Pro-
nounced astrocytosis has been detected in these mice at 4 months of age and microg-
lial activation rather late at 12 months of age (von Schantz et al., 2009). Gene ex-
pression profiling has pinpointed to early upregulation of immune response genes 
(Kopra et al., 2004). 
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In this thesis project a mouse model lacking both genes was generated and is de-
scribed in the Material and Methods section. The neuropathological features in the 
two knockout mouse models, which have been reported prior to this thesis work are 
summarised in Table 2. 
 
MOUSE MODEL Cln1 ko Cln5 ko 
Onset of symptoms >5 months > 8 months 
Phenotype Seizures and motor  disturbancesa 
Seizures and motor  
disturbancesb 
Ultrastructure of  
storage material GROD
a RL, FP, CLb 
Onset of neuron loss Thalamus (4months)c Cortex lam IV and V (4months)c 
Reactive astrocytosis 
(GFAP) 
Cortex and thalamus 
(3months)a 
Cortex and thalamus 
(3months)c 
Microglial activation 
(F4/80) 
Cortex and thalamus 
(3months)a 
Cortex and thalamus 
(12 months)c 
 
Table 2: overview of neuropathological changes reported prior to this thesis work 
in NCL knockout mouse models used in this thesis. Ppt1Δex4 equates Cln1 ko and 
Cln5-/- equates Cln5 ko (the nomenclature used throughout this thesis work). 
Abbreviations: CL, curvilinear profile; FP, fingerprint profile; GFAP, glial fibrillary 
acidic protein; GROD, granular osmiophilic deposits; RL, rectilinear profile. aJalanko et 
al., 2005 and unpublished; bKopra et al., 2004 and unpublished; cvon Schantz et al., 
2008 
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3 Aims of the present study 
Prior to this study, the Cln5 gene, defective in CLN5 disease, late infantile variant 
NCL, has been identified and knockout mouse models for Cln1 and Cln5 were 
available. Following aims were addressed in this study: 
 
• Characterisation of the basic properties of the CLN5 protein in 
more detail with focus on processing, localisation and trafficking 
within the cell. 
• Analysis of the consequences of mutations in the CLN5 gene on 
its localisation in the cell. 
• Analysis of the Cln5 expression in the mouse brain. 
• Verification of the impact of Cln5-deficiency in the mouse brain, 
focusing on microglial activation and myelination defects. 
• Analysis of the functional importance of Cln5 in lipid homeostasis. 
• Investigation of possible links between Cln5 and its suggested 
interaction partner Cln1/Ppt1 by characterising a Cln1/5 double-
knockout mouse model. 
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4 Materials and Methods 
4.1 Materials and methods 
An overview of the methods used in this thesis is given in Table 3. Brief general 
descriptions of the techniques are also described here. More details are available in 
the original publications.  
 
Table 3: list of methods used during this thesis. 
METHODS 
ORIGINAL  
 PUBLICATION 
CHAPTER 
Analysis of protein maturation and glycosylation  I 4.1.10 
Basic staining techniques of mouse tissue: LFB, Nissl II+III 4.1.13 
Cell culturing of SH-SY5Y, COS-1, HeLa, MPR-/- cells I 4.1.3 
Efflux studies of [3H] cholesterol to apoA-I II 4.1.18 
Gene expression profiling III 4.1.7 
Generation of Cln1/5 double-knockout mice III 4.1.1 
Generation of iPS cells and embryoid body formation III 4.1.5 
Image thresholding analysis II 4.1.17 
Immunofluorescence staining I+II 4.1.9 
Immunohistochemical staining and analysis of paraffin 
and free floating mouse brain sections II+III 4.1.16 
In vitro LPS stimulation of mouse primary microglia and 
mouse cytokine array II 4.1.12 
Light, confocal, fluorescence, electron microscopy I-III 4.1.9; 4.1.13 
Measurements of thickness and regional volume of mouse 
brain II+III 4.1.14 
Mouse brain isolation and histological processing  II+III 4.1.13 
Neuron cell counts III 4.1.15 
Primary cells: isolation and culture of neurons, oligoden-
drocytes, microglia, astrocytes and peritoneal macro-
phages 
II 4.1.4 
Pulse-chase analysis with [35S] and immunoprecipitation I 4.1.10 
Pulse-chase of BODIPY-LacCer  II 4.1.18 
Quantitative real-time PCR II 4.1.6 
Recombinant DNA techniques and site-directed mutagenesis I 4.1.2 
Reverse transcriptase PCR II+III 4.1.6 
RNA extraction from mouse brain and cell cultures II+III 4.1.6 
SDS-PAGE and Western Blot analysis I+III 4.1.11 
Serum lipid analysis II+III 4.1.18 
Transient and stable transfections of cell lines I 4.1.3 
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4.1.1 Cln1 ko, Cln5 ko mice and generation of Cln1/5 double-knockout 
mice (II+III) 
Homozygous Cln1 ko and Cln5 ko mice, maintained on the C57BL/6JRcc back-
ground have been developed prior to this study and were available for further studies 
(Jalanko et al., 2005; Kopra et al., 2004). We crossed these mice to generate first 
heterozygous and later Cln1/Cln5-double-knockout (Cln1/5 dko) offspring. The 
Cln1/5 dko offspring were viable and fertile. C57BL/6JRcc wild-type (wt) mice 
served as a control strain. The genotypes of all mice were verified by polymerase 
chain reaction (PCR) of DNA from tail biopsies (Jalanko et al., 2005; Kopra et al., 
2004). 
4.1.2 Expression constructs and site-directed mutagenesis (I+unpubl.) 
Human wild-type CLN5–pCMV5 (aa 1–407) and CLN5–pCMV5 carrying the dif-
ferent disease causing mutations p.Y392X, p.E253X, p.D279N were available prior 
to the studies (described by Isosomppi et al., 2002; Vesa et al., 2002). CLN5 con-
structs carrying the mutations p.R112P and p.R112H mutations were generated into 
CLN5–pCMV5 construct by site-directed in vitro mutagenesis, using the Quick-
Change mutagenesis kit from Stratagene. All used expression constructs of mutated 
CLN5 start from the first methionine (M1). GFP–CLN5 constructs starting from 
methionines M1-M4 were cloned in frame with an N-terminal GFP-tag in vector 
pEGFP-C1. Full-length mouse Cln5 cDNA (aa 1–341) with a C-terminal myc/his-
tag, was developed by cloning the Cln5cDNA into pcDNA3.1A/myc–his expression 
vector. The construction of CLN1–pCMV5 and CLN3-pCM5 were described earlier 
(Järvelä et al., 1998; Salonen et al., 2000). All constructs were verified by sequen-
cing. 
4.1.3 Cell culturing and transfections (I + unpublished) 
Human cervical cancer cells (HeLa) and African green monkey kidney cells (COS-
1) were cultured in Dulbecco’s modified Eagle´s medium (DMEM) (+10% fetal calf 
serum (FCS), 1% penicillin/streptomycin (PS)). Human neuroblastoma cells (SH-
SY5Y) were maintained in DMEM:Ham’s F12 medium (+10% FCS, PS, 0.1% non-
essential amino acids). Transient transfections were done with Fugene HD transfec-
tion reagent. A stable cell line expressing CLN5 was established (CLN5-SH-SY5Y) 
by co-transfecting cells with human CLN5–pCMV5 and pREP4 vector (hygromycin 
B resistance). Mannose-6-phosphate-receptor double-deficient mouse fibroblasts 
(MPR-/-, MPR46- and MPR300-deficient) were provided by Thomas Braulke (Ger-
many) (Pohlmann et al., 1995). The MPR-/- cells were cultured in DMEM (+20% 
FCS, 1% PS). Transient transfection of MPR-/- cells was done with Lipofectamine 
2000 transfection reagent.  
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4.1.4 Cell culture of mouse primary neurons, glial cells and peritoneal 
macrophages (II) 
Mouse embryonic fibroblasts (MEFs) from E16.5 old mice were cultivated in 
DMEM (+20% FCS, 1% PS). Peritoneal macrophages were obtained from 2-6 
month old mice into phosphate buffered-saline (PBS) (+Ca2+, Mg2+)/0.1% BSA 
(bovine serum albumin) (see publication II for further details). Mouse cortical neu-
rons were prepared from mouse embryos 14.5-16.5 days post-fertilisation. Cerebral 
hemispheres were removed and placed in ice-cold 20 mM glucose/PBS. The menin-
ges and blood vessels were carefully removed and cortical tissues were separated. 
Individual cells were isolated by trituration in 1 ml PBS, and incubated in trypsin-
EDTA/DNaseI (0.1%/0.4 mM/10 mg/ml) for 5 min at 37°C. Trypsin was inactivated 
by FCS. The cells were centrifuged at 1000 rpm for 2 min and resuspended in Neu-
robasal media (+B-27, 0.5 mM L-glutamine and 1% PS). Two hemispheres were 
plated per poly-D-lysine hydrobromide (PDL)-coated 6-well plate. Two-thirds of the 
culture medium were replaced every fourth day. Mouse oligodendroglial cultures 
were prepared from mouse embryos E16.5 days post-fertilisation. The preparation 
steps were essentially the same as for the cortical neurons until after the centrifuga-
tion step. The cells were then resuspended in DMEM/F-12 media (+B-27, 40 ng/ml 
fibroblast growth factor (FGF; Sigma-Aldrich), 20 ng/ml epidermal growth factor 
(EGF), 1% PS). 50000 cells/ml were transferred to an uncoated 12-well plate. After 
3-6 days the cells were triturated and transferred to oligosphere medium (DMEM/F-
12 + B27, 10 ng/ml FGF, 10ng/ml platelet derived growth factor (PDGF), 1% PS). 
The cells were passaged every 3 days. After 1-2 passages cells were mechanically 
triturated, centrifuged at 1000 rpm for 2 min and the resuspended in fresh medium. 
100.000-150000 cells/well were placed to a poly-L-ornithine hydrochloride (PO)-
coated 6-well plate. After 3-4 days the medium was replaced by DMEM (+B27, 3% 
FCS, 1% PS). OLs were fixed with 4% PFA/PBS at different time points post-
differentiation. Primary cultures of purified microglia and astrocytes were obtained 
from 3day old mice. Following decapitation, the brains were isolated and washed in 
ice-cold 20 mM glucose/PBS. Cerebral hemispheres were dissected and the menin-
ges removed. The hemispheres were trypsinised in 1 ml PBS + trypsin-
EDTA/DNaseI for 20 min at 37°C. Trypsin was inactivated by FCS, cells were cen-
trifuged for 5min at 1000 rpm and resuspended in DMEM (+1% PS, 10% FCS). One 
hemisphere was plated per PO-coated T-75 cell culture flask two-thirds of the cul-
ture medium were replaced every third day. After 10-14 days the microglial cells 
were selectively detached from the flasks by shaking (2 h, 37°C, 225 rpm) on a ro-
tary shaker. Suspended microglia were seeded and after 2h medium was replaced to 
remove loosely adhered cells (Eagle-MEM, 2mM L-glutamine, 1% PS, 10% FCS, 
5ng/ml mouse macrophage-colony stimulating factor (M-CSF). Purified astrocytes 
were obtained by adding fresh medium to the cells which were still attached after the 
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primary shaking and a following shaking for 16-18 hours at 300 rpm. The suspended 
cells were transferred to an uncoated cell culture dish and after 1h the medium re-
placed.  
4.1.5 iPS (induced pluripotent stem) cell studies (III) 
The experiments and protocols of iPS cell studies are described in detail in publica-
tion III and therefore only shortly described here. In brief, MEFs were repro-
grammed by retrovirus-mediated delivery of the four Yamanaka factors (Oct3/4, 
Sox2, Klf4 and c-myc) (Takahashi et al., 2007). iPS cell clones were grown on LIF-
producing SNL-feeder cells, collected on the basis of colony morphology, expanded 
and purified by MACS anti-stage-specific embryonic antigen 1 (SSEA-1) Mi-
croBeads (Miltenyi Biotech). The clones were analysed with an ES cell characterisa-
tion kit (Millipore) and by RT-PCR (for more details see publication III). 
Embryoid bodies (EB) were grown in suspension in ES medium. On day seven, the 
size of the EBs was determined by a microscopic analysis. Pluripotency of the pro-
duced iPS cell clones was analysed by staining the spontaneously differentiated cells 
with anti-FoxA2 anti-β-III tubulin or anti-desmin antibodies (Table 4) to stain 
endoderm, ectoderm and mesoderm. 
4.1.6 RNA extraction and real-time PCR (II+III) 
In short, for real-time PCR RNA of mouse brain hemispheres or cells was extracted 
and quantified by NanoDrop. Genomic DNA was removed with DNAseI. TaqMan 
Reverse transcription kit with Random hexamer primers was used for the reverse 
transcription reactions. The mRNA expression levels were measured with real-time 
PCR analysis on an ABI prism 7700 sequence detection system. The detailed pa-
rameters can be seen in study II + III. Relative levels of the selected genes were 
calculated using the ΔΔCT method (Livak and Schmittgen, 2001).  
4.1.7 Gene expression profiling (III) 
In brief, RNA was isolated from mouse cortices and its purity determined by Agilent 
2100 Bioanalyzer. Its concentration was measured with NanoDrop, labelled and 
fragmented; followed by hybridisation, post-hybridization washes, staining and 
scanning. Gene expression profiles were determined with the Illumina MouseWG-6 
v2.0 Expression BeadChip and Genome Studio Data Analysis Software. Chipster 
v1.4.7 analysis software was used for gene expression analyses. Pathway analyses 
were done with DAVID Bioinformatics Resources 6.7 software. For further details 
see study III. 
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4.1.8 Used antibodies (I-III) 
Table 4: overview of primary antibodies used in this thesis. 
 
antibody organism dilution company/reference target study 
Immunofluorescence experiments 
1D3 mouse 1:50 Stressgen ER marker (PDI) I 
1D4B rat 1:100 Developmental 
studies Hybri-
doma bank 
Mouse lysosomal marker 
(LAMP-1) 
I 
1GmII-3 guinea pig 1:100 (Holmberg et al., 
2004) 
Cln5 I 
1RmI-4 rabbit 1:500 (Holmberg et al., 
2004) 
Cln5 I 
AB5320 rabbit 1:200 Millipore OPC marker (NG-2) II 
β-III  
tubulin 
rabbit 1:1000 Covance ectoderm III 
Desmin rabbit 1:500 Epitomics mesoderm III 
FoxA2 goat 1:1000 Santa Cruz endoderm III 
H4A3 mouse 1:100 Developmental 
studies Hybri-
doma bank 
Human lysosomal marker 
(LAMP-1) 
I 
m385 rabbit 1:300 (Luiro et al., 
2001) 
CLN3 aa242-258 I 
MAB 386 rat 1:100 Millipore Differentiated OLs (MBP) II 
SMI91R mouse 1:200 Covance OLs (CNPase) II 
Western Blot analysis 
GFP mouse 1:2000 Santa Cruz GFP I 
CLN5-
C/32 
rabbit 1:300-
1:500 
(Schmiedt et al., 
2010) 
Human CLN5 aa392-407 I 
β-tubilin mouse 1:1000 Chemicon β-tubilin (loading control) III 
α-syn. mouse 1:1000 BD Biosciences α -synuclein III 
Immunohistochemistry 
CD68 Rat 1:1000 Serotec Activated microglia II+III 
GFAP rabbit 1:4000 DAKO astrocytosis III 
IBA-1 rabbit 1:100 Menarini Microglia II 
MBP Rat 1:500 Millipore OLs II+III 
α-syn. 
&#945 
rabbit 1:1000 gift by prof. M.G. 
Schlossmacher 
α-synuclein, raised and 
affinity-purified at Open   
Biosystems 
III 
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Table 5: overview of secondary antibodies used in this thesis. 
 
Antibody organism dilution Company/reference Conjugated to study 
Immunofluorescence experiments 
a-guinea pig goat 1:200 Jackson Immu-
noResearch 
TRITC I 
a-rabbit Goat or 
donkey 
1:200 Jackson Immu-
noResearch 
Cy5, TR II+III 
a-mouse goat or 
donkey 
1:200 Jackson Immu-
noResearch 
Cy5, TR, FITC I+III 
a-rat Goat or 
donkey 
1:200 Jackson Immu-
noResearch 
Cy5 I+II 
Western Blot analysis 
a-rabbit swine 1:10000 DAKO HRP I 
a-mouse goat 1:5000 DAKO HRP I+III 
Immunohistochemistry 
a-rat Rabbit 1:1000 Vector laboratories biotinylated II+III 
a-mouse goat 1:200 Vector laboratories biotinylated III 
a-rabbit goat 1:1000 Vector laboratories biotinylated II 
4.1.9 Immunofluorescence (IF) staining and microscopy (I+II) 
For IF analysis, cells were fixed in ice cold methanol or 4% paraformaldehyde/PBS 
(PFA). After fixation cells were blocked by incubating them with 0.5% BSA in PBS 
or in case of PFA fixation in PBS supplemented with 0.2% saponin and 0.5% BSA. 
Primary antibodies (Table 4) were diluted in PBS (0.5% BSA or 0.5% BSA/0.2% 
saponin) and incubated for 1 h. Excess antibodies were removed by washing the 
cells three times with PBS (0.5% BSA or 0.5% BSA/0.2 % saponin). Secondary 
antibodies (Table 5) were also diluted in PBS (0.5% BSA or 0.5% BSA/0.2% sapo-
nin) and the cells incubated for 1h. After washing the cells three times with PBS the 
labelled coverslips were mounted with GelMount and visualised with a Leica DMR 
confocal microscope or with an Axio Imager.Z1 microscope. 
4.1.10 Analysis of CLN5 protein maturation and glycosylation (I) 
Many tools are available to analyse intracellular trafficking and maturation in cell 
culture systems. It is important to keep in mind that there are no absolutely fixed 
resident components of compartments but proteins/lipids are continually moving 
between different compartments. The balance of traffic between the compartments 
determines the steady-state localisation (Watson et al., 2005). Pulse-chase experi-
ments are powerful tools to analyse e.g. biosynthesis, protein maturation and protein 
degradation. Metabolic labelling with low energy ß-emitting isotopes radioisotopes 
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like [35S] methionine is widely used as it is incorporated into newly synthesised 
proteins and relatively stable. The actual experiment can be divided into three steps: 
the pulse-chase, immunoprecipitation of the protein of interest and finally SDS-
PAGE and detection of the signal. However, results using this method should be 
verified by a second method as this type of labelling inhibits cell proliferation, in-
duces cell cycle arrest and may alter the cell morphology (Hu and Heikka, 2000). 
CLN5-SH-SY5Y cells were metabolically labelled by starving them in methionine-
free DMEM and thereafter labelling with [35S] methionine. Not internalised label 
was removed and the cells were chased in medium. Cell lysates were immunopre-
cipitated with CLN5-C/32 antibody (Table 4) and A/G sepharose beads. The sam-
ples were separated by SDS-PAGE and the gel was fixed. The radioactive signal 
was intensified with sodium salicylate. The dried gel was exposed to an autoradio-
graphic film. 
To verify the pulse-chase results protein synthesis was blocked by treating the cells 
with 50 µg/ml cycloheximide (CHX) up to 24 h. Anterograde trafficking between 
the ER and Golgi apparatus was analysed by cell treatment with 2.5 µg/ml brefeldin 
A (BFA), which blocks the anterograde trafficking. Protein N-glycosylation was 
studied by cell treatment with a dolichol pyrophosphate-N-acetylglucosamine inhibi-
tor 10 µg/ml tunicamycin. To deglycosylate proteins to analyse their posttransla-
tional modifications peptide N-glycosidase F (PNGaseF) was used. PNGaseF 
cleaves between the innermost GlcNAc and asparagine residues of high mannose, 
hybrid, and complex oligosaccharides from N-linked glycoproteins. Also, endogly-
cosidase H (EndoH) was used that removes Asn-linked mannose-rich N-glycans, but 
not complex type sugars (see publication I for further details). Samples were sepa-
rated by SDS-PAGE, immunoblotted and then probed for CLN5. 
4.1.11 SDS-PAGE and Western Blot analysis (I+III) 
Protein concentration of the samples (study I: cell lysates or study III: mouse brain 
extracts) was determined with a DC protein assay and equalised amounts of total 
protein were analysed. The samples were denaturised at 95°C with Laemmli buffer 
containing 2% β-mercaptoethanol for 5 min, samples were loaded and separated on 
10-14% SDS-PAGE gels. Proteins were transferred to nitrocellulose membranes 
(Amersham Biosciences) by electroblotting at 400 mA for 1 h. Afterwards Ponceau 
protein stain was used to confirm protein loading and even transfer. Skimmed milk 
powder (5%) in tris buffered saline–tween (TBS-T) was used for blocking and as 
dilution buffer for primary antibodies (Table 4), TBS-T for the secondary horserad-
ish peroxidase (HRP)-conjugated antibodies (Table 5). For the detection of antigens 
enhanced chemiluminescence (ECL) was used as HRP substrate. 
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4.1.12 Mouse cytokine array (II) 
Briefly, mouse primary microglia were treated with Escherichia coli lipopolysaccha-
ride (LPS) or no stimulant. 24 h later media was changed to medium without any 
supplements. 48 h later the supernatant was collected and cells were harvested for 
determination of protein concentration. The cytokine levels in the culture media 
were determined using the mouse cytokine array panel A (Proteome ProfilerTM Ar-
ray). Data was captured by exposure to Fuji medical x-ray films. Arrays were 
scanned and optical densities were determined with imageJ. 
4.1.13 Mouse brain preparation, electron microscopy (EM), autofluorescence 
detection and basic stainings of mouse brain tissue (II+III) 
For EM analyses (III), bisected brains were immersion fixed in 0.1 M phosphate 
buffer pH 7.4/4% PFA/2.5% glutaraldehyde, incubated in fresh fix solution, and 
stored in 10mM phosphate buffer. Cortical and thalamic pieces were osmicated, 
dehydrated and embedded in epoxy resin. Ultra thin sections were contrasted with 
uranyl acetate and lead citrate. The sections were viewed and analysed with a JEOL 
1400 Transmission Electron Microscope, and images were taken using a Digital 
Camera Olympus-SIS Morada, 36 x 24 mm CCD, 11 Mega pixels, pixel size: 9 µm. 
For Nissl (II+III), Luxol Fast Blue (LFB) (II), autofluorescence detection (III) and 
most immunohistochemical stainings (II+III) mice were deeply anesthetised with 
Ketalar®/Rompun® vet (2:1) and transcardially perfused with vascular rinse PBS 
and by a fresh solution of 4% PFA. Brains were isolated and postfixed in 4% PFA. 
The brain samples were cryoprotected in a solution of 30% sucrose/TBS containing 
0.05% NaN3 for a minimum of 48 h, then frozen and stored at −70°C. Next, for 
further preparation brains were bisected along the midline, and 40μm frozen coronal 
sections were cut with a sliding microtome through the rostrocaudal extent of the 
cortical mantle (Figure 8). Sections were collected into 96-well plates containing 
cryoprotectant solution. 
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Figure 8: schematic sagital view of an adult mouse brain. For immunohistochemical 
analysis coronal sections were cut through one hemisphere of a mouse brain. Modified 
from The Mouse Brain in Stereotaxic Coordinates (Paxinos and Franklin, 2001). 
 
For some immunohistochemical stainings, mouse brains were fixed in 4% PFA, 
embedded in paraffin and sectioned at 5 µm (III). Sections were deparaffinised, 
rehydrated in alcohol series, incubated in 5% H2O2, and rinsed with TBS. The sec-
tions were boiled in Na-citrate buffer (pH 6.0), blocked and incubated with primary 
antibody (Table 4). Next, samples were rinsed with TBS-T and incubated with 
secondary antibody (Table 5). The sections were treated with avidin-biotinylated 
HRP complex, washed with TBS and treated with 3,3′-diaminobenzidine tetrahydro-
chloride HCl (DAB). Subsequently, sections were counterstained with haematoxylin. 
After dehydration, the sections were cleared in xylene, air-dried and coverslipped 
with p-xylene-bis(pyridinium bromide) DPX. To analyse the extent of endogenous 
autofluorescence mouse brain sections were mounted onto chrome-gelatine coated 
slides and coverslipped with Vectashield. Images from each section were captured 
using a Leica SP5 confocal microscope and a 488 nm excitation laser. For Nissl 
staining, a classic nucleic acid staining traditionally used on nervous tissue sections 
(II + III), the mounted brain slices were incubated with 0.05% cresyl fast violet/ 
0.05% acetic acid in water, rinsed in distilled water and differentiated through an 
ascending series of ethanol, cleared in xylene, and finally coverslipped with DPX. 
LFB staining was used to stain myelin (II). The sections were first rinsed in deion-
ised water, then in 70% ethanol, then in 95% ethanol, followed by the staining step 
overnight with 0.1% LFB in 95% ethanol at 60oC. Unbound stain was removed by a 
washing step in deionised water. The LFB stain was differentiated by a brief rinse in 
0.05% lithium carbonate followed by 70% ethanol. The sections were rinsed in de-
ionised water and counterstained in 0.05% Cresyl Fast Violet solution for 20 min at 
60oC. Sections were rinsed in deionised water, 70% ethanol and dehydrated through 
increasing ethanol concentrations, cleared in xylene and coverslipped with DPX.  
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4.1.14 Thickness and regional volume measurements (II+III) 
Stereological estimates were obtained with StereoInvestigator software (Micro-
brightfield Inc). First, a one in six series of mouse brain sections were Nissl stained 
(see 4.1.13). Regions of interest (ROI) were defined by referring to the neuroana-
tomical landmarks as described in Paxinos and Franklin, 2001. A sampling grid was 
superimposed over the ROI and the number of points covering the area was assessed. 
The volume in µm3 was estimated from a series of sections through each ROI (for 
further details see original publication II and III). Analyses were carried out on an 
Olympus BX50 microscope linked to a DAGE-MTI CCD-100 camera. The mean 
coefficient of error for all Cavalieri estimates was determined using the method of 
Gundersen and Jensen (1987) and was less than 0.05. For thickness measurements of 
brain regions ten perpendicular lines were traced from the pial surface of the cortex 
to the white matter of the corpus callosum (III). The mean length was taken as a 
measure of thickness and this was determined in three consecutive sections from a 
defined rostrocaudal level for each analysed region (Bible et al., 2004; Kielar et al., 
2007). 
4.1.15  Neuron counts (III) 
For the quantification of the neuronal cell number Nissl-stained mouse brain sec-
tions were used from a 1:6 series and a design-based optical fractionator probe was 
utilised. A ROI was determined, a grid superimposed and cells were counted with a 
100x objective within a series of dissector frames. Grid and dissector sizes were 
chosen according to each brain region using a coefficient of error (CE) value of ≤ 
0.1 to indicate sampling efficiency. All neuron counts were done with a Zeiss, Ax-
ioskop 2 MOT microscope linked to a DAGE-MTI CCD-100 camera. 
4.1.16 Immunohistochemistry (II+III) 
One in six series of brain sections were treated with 1% H2O2 in TBS for 20 min to 
quench endogenous peroxidase activity. Next, the sections were washed in TBS, 
blocked with 15% serum/TBS for 40 min and then incubated with specific primary 
antibodies (Table 4), which were diluted in TBS (+0.3% Triton X-100, 10% 
goat/rabbit serum). Next, the sections were rinsed with TBS and subsequently incu-
bated in the according biotinylated secondary antisera (Table 5) in TBS (+0.3% 
Triton X-100, 10% normal serum). The sections were rinsed in TBS, incubated with 
an avidin–biotinylated peroxidase complex in TBS, rinsed in TBS, and immunoreac-
tivity was detected by incubation in 0.05% DAB and 0.001% H2O2 in TBS. Ice-cold 
TBS was added to the sections which were then rinsed, mounted, air-dried, cleared 
in xylene, and coverslipped with DPX.  
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4.1.17 Image thresholding analysis (II) 
The optical densities were obtained by semi-automated thresholding image analysis 
(Bible et al., 2004). Thirty non-overlapping images were taken from 3 consecutive 
brain sections starting from a defined anatomical landmark. The area of immuno-
reactivity was determined with Image Pro Plus image analysis software. Thereby, a 
threshold that discriminated staining from background in each image was applied. 
Data were plotted as the mean percentage area of immunoreactivity per field for 
each region. 
4.1.18 Lipid metabolism studies (II+III) 
To study systemic lipid disturbances blood for serum lipid and lipoprotein analysis 
was collected from mice (see studies II+III). Total cholesterol was determined en-
zymatically in mouse serum via a series of coupled reactions that hydrolyse cho-
lesteryl esters and oxidise the 3-OH group of cholesterol (CHOD-PAP 1489232 kit, 
Roche Diagnostics). The reaction byproduct hydrogen peroxide was measured quan-
titatively in a peroxidase catalysed reaction that produced a colour. The colour in-
tensity is proportional to the cholesterol concentration and therefore the absorbance 
was measured at 500 nm. Also, triglycerides were measured enzymatically in mouse 
serum using a series of coupled reactions in which triglycerides were hydrolysed to 
produce glycerol (GPO-PAP 1488872 kit, Roche Diagnostics). Glycerol then in turn 
was oxidised using glycerol oxidase, and hydrogen peroxide one of the reaction 
products, was measured as described for cholesterol. PLTP activity was determined 
with a radiometric assay (Jauhiainen and Ehnholm, 2005). In short, the activity is 
detected as transfer of radioactively labelled phospholipids from donor liposomes to 
acceptor HDL particles. Radioactivity was measured from supernatants, which con-
tain the loaded HDL particles and PLTP with a liquid scintillation counter. Mouse 
apoA-I was quantified using a sandwich enzyme-linked immunosorbent assay 
(ELISA) with use of a polyclonal rabbit anti-mouse apoA-I IgG, performed in 96-
well plates coated with this antibody. Purified mouse apoA-I was used as a primary 
standard. Serum samples were diluted in PBS-Tween 20 (0.1%) + 0.5% BSA. 
Bound apoA-I was detected by the addition of polyclonal rabbit anti-mouse apoA-I, 
conjugated to HRP. The assay was linear in the range of 6.5-420 ng/ml. In the 
paraoxonase-1 (PON-1) activity assay, paraoxon (diethyl-p-nitrophenylphosphate) 
was used as a substrate (Gan et al., 1991). Briefly, 20 µl serum was added to buffer-
substrate solution (100 mM Tris-HCl, pH 8.0, 1 mM CaCl2, 1.2 mM paraoxon) and 
incubated at 37°C for 10 min. PON converts paraoxon to p-nitrophenol, a yellow 
compound that is measured at 405 nm. The activity unit is µmol/min. For the lipo-
protein analysis, serum samples were fractionated by fast-performance liquid chro-
matography (FPLC). 
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For cholesterol uptake and efflux analyses, peritoneal macrophages were incubated 
with [3H]cholesterol-LDL. Unattached LDL particles were removed by a washing 
step. To evaluate the uptake, cells were scraped and scintillation counted. To meas-
ure the efflux, the macrophages were washed with PBS after labelling, incubated 
with apoA-I, the medium collected and the cells washed with PBS. The medium and 
cell lysates scintillation counted. To study the fluorescent sphingolipid transport, 
peritoneal macrophages were incubated with EMEM + boron dipyrromethene 
(BODIPY) FLC5-lactosylceramide (BODIPY-LacCer). BODIPY is an effective 
biological label since it has been reported to have a superior photostability compared 
to fluorescein and is relatively insensitive to changes in polarity and pH values (Ul-
rich et al., 2008). Fluorescent sphingolipids can be used as fluorescent structural 
markers for the Golgi compartment, as tracers of lipid metabolism and trafficking of 
lipid endocytosis pathways can be followed (Pagano and Chen, 1998; Pagano et al., 
1991). BODIPY-LacCer is known to be internalised via caveolae and reaches early 
lysosomes within few minutes from where it either recycles back to the cell surface 
or via late endosomes to the Golgi compartment (Choudhury et al., 2002; Choud-
hury et al., 2004; Sharma et al., 2003). Further, cellular identification of lysosomal 
lipid storage disorder phenotypes is possible with BODIPY-LacCer as the traffick-
ing towards the Golgi compartment is disturbed in these diseases (Puri et al., 1999). 
In the experiments, the PM labelling was assessed in the beginning and the label was 
chased for several time-points. The BODIPY-LacCer internalisation was imaged 
with fluorescence microscopy (for details see study II). 
4.2 Ethical aspects 
The studies were performed in accordance with approved animal policies of the 
National Institute for Health and Welfare and the University of Helsinki and the 
State Provincial offices of Finland (agreement numbers ESLH 2009-05074/STH 415, 
KEK09-058 and KEK09-060). The work has been carried out following good prac-
tise in laboratory animal handling and the regulations for handling genetically modi-
fied organisms.  
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5 Results and discussion 
5.1 The CLN5 protein (I+II) 
5.1.1 Cln5 expression in the brain and cells of the CNS (II) 
It has been reported earlier that Cln5 is expressed in mouse brain and all other pe-
ripheral organs (heart, kidney, lung, liver, skeletal muscle, spleen, testis) tested by 
Northern Blot analysis (Holmberg et al., 2004). Further, Cln5 expression in mouse 
brain has been detected at embryonic stage E13 and was shown to be elevated at the 
age of 1 month also by Northern hybridisation (Holmberg et al., 2004). Reverse 
transcriptase PCR studies detected Cln5 in cell cultures representing different cell 
populations of the embryonic mouse brain (mixed glial cells, hippocampus, cortex, 
total brain) (Holmberg et al., 2004). In situ hybridisation analysis of Cln5 mRNA 
showed widespread expression in E15 old mice being more abundant in the develop-
ing cerebellar cortex, cerebellum and the ganglionic eminence (Holmberg et al., 
2004). Immunohistochemical staining of Cln5 in mouse brain sections of postnatal 
mice detected immunoreactivity in Purkinje cells, diverse cortical neurons, hippo-
campal pyramidal cells and glia (not further specified) in P7 up to 2 month old mice 
(Holmberg et al., 2004). 
One aim of this thesis was to elucidate the Cln5 gene expression among the different 
cell types in the mouse CNS by qPCR analyses. Therefore, mRNA was extracted 
from separately cultured neurons, astrocytes, oligodendrocytes and microglia from 
wt mice (C57BL/6JRccHsd). RT-PCR indicated that Cln5 expression levels among 
cells of the CNS were highest in microglia, followed by astrocytes, oligodendrocytes 
and neurons in descending order (Table 6 and II; Figure 1B). Additionally, Cln5 
expression levels were significantly increased in microglia (three-fold) after stimu-
lating cells with LPS, which causes immune responses and activates microglial cells. 
This indicates a possible role for Cln5 in immune response (II; Figure 1C). More-
over, the gene expression was analysed over life time in mouse brain. The overall 
expression levels of Cln5 increased gradually in mice from 3 days up to 3 months of 
age, where it then reached a plateau (II; Figure 1A). This indicates that Cln5 ex-
pression may play a role in brain development. Interestingly, distinct differences in 
the gene expression patterns of NCL types have have been reported. For example, 
gene expression of Cln1 and Cln5 has been suggested to be under developmental 
control, whereas the expression levels for Cln2 and Cln10 have been shown to re-
main constant during development (Holmberg et al., 2004; Suopanki et al., 2000). 
Interestingly, the expression levels of NCL genes vary highly between neurons and 
different types of glial cells in rodents (rats, mice, see Table 6) although neuron-
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specific death is a hallmark in all forms of NCL. However, it is noteworthy that 
these findings of gene expression levels in different cell types may not reflect the 
protein expression levels and consequently, the function of NCL proteins. Only 
analyses on protein level can verify these findings. Also, human CLN5 expression 
needs to be verified over life-time to see at which age CLN5 protein reaches its plat-
eau in healthy humans. 
 
GENE neurons astrocytes microglia OLs 
Cln1    n.d. 
Cln2    n.d. 
Cln3    n.d. 
Cln5     
Cln7    n.d. 
Cln10    n.d. 
 
Table 6: gene expression levels of NCL genes in different cell types of the CNS from 
mice (Cln5) and rats (Cln1-3, 7, 10) cell cultures. Black filling indicates the highest 
gene expression; followed by dark grey, light grey and white. Same colours within one 
row indicate similar expression levels (e.g. for Cln1 neurons ≈ astrocytes > microglia). 
Abbreviations: n.d., not determined; OLs, oligodendrocytes. The table was assembled 
using data from Sharifi et al., 2010 and study II. 
 
The finding that expression of NCL genes is distributed differently between the 
various CNS cells is supported by the different pathological profiles of the NCL 
mouse models, when all events like neuronal loss, astrocytosis and microglial acti-
vation are taken into consideration (Cooper, 2010). However, it is remarkable that 
different gene products lead to a similar pathological endpoint. It remains to be clari-
fied if NCLs are truly connected on protein level in vivo, like it has been indicated 
by in vitro studies (Lyly et al., 2009; Vesa et al., 2002). 
5.1.2 Maturation and trafficking to the lysosomes (I) 
Prior to this study, controversial characteristics about the CLN5 protein maturation, 
localisation and solubility have been published (Bessa et al., 2006; Holmberg et al., 
2004; Isosomppi et al., 2002; Savukoski et al., 1998; Vesa et al., 2002). In cell cul-
ture based transient overexpression analyses CLN5 protein has been suggested to be 
an ER resident (Vesa et al., 2002) and a lysosomal protein (Isosomppi et al., 2002; 
Vesa et al., 2002). Further, it was under debate whether CLN5 is a transmembrane 
protein (Bessa et al., 2006; Savukoski et al., 1998; Vesa et al., 2002) or a soluble 
protein (Holmberg et al., 2004). However, the fact that CLN5 contains M6P residues 
on high mannose-type sugars that are connected to Asn320/330 and 401 pinpoint to 
a soluble CLN5 protein (Sleat et al., 2006). One goal of this thesis work was to shed 
light onto these controversies about the CLN5 protein.  
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Earlier theoretical prediction studies did not suggest an ER signal peptide to be pres-
ent in the CLN5 sequence. However, only the sequence starting from M1 was taken 
into consideration although the Cln5 sequence in mouse starts from methionine cor-
responding to M4 in humans (Savukoski et al., 1998). Simulations for all four M1-
M4 sequences presented herein (I; Supp. Table S1), predicted the existence of a 
signal peptide for the sequences starting from M2-M4 with different probabilities 
(SignalP). In accordance, it was shown earlier that four forms of CLN5 were trans-
lated in a cell-free system in vitro (Isosomppi et al., 2002).  
To address the question if all or only some of the methionines can be used as initi-
ation points and if CLN5 may be cleaved, COS-1 and HeLa cells were transiently 
transfected with several constructs. The constructs contained GFP-tags introduced at 
the 5’ end of each initiation methionine of the human CLN5 sequence (Figure 9A 
and I; Figure 1A). The expressed proteins were analysed by immunofluorescence 
and SDS-PAGE, followed by Western Blotting. GFP and a novel human specific C-
terminal CLN5 antibody were utilised to detect both extremities of the overex-
pressed protein constructs. The novel antibody was raised against a synthetic peptide 
against the very C-terminal end of CLN5. As it detected the CLN5 protein in West-
ern Blotting analyses, this indicated that CLN5 is not trimmed at the C-terminus. 
Further, the novel CLN5 antibody recognised a single 60 kDa protein for all M1-M4 
constructs, whereas the GFP antibody detected proteins of variable molecular 
weights (Figure 9B and I; Figure 1B-C). The molecular weights correlated well 
with the estimated N-terminal fragment sizes assuming a signal peptide cleavage at 
the same site in all constructs. Based on the topology programmes this cleavage 
would occur at the amino acid position 96. Immunofluorescence observations sup-
ported the hypothesis of an N-terminal signal cleavage site regardless of the initi-
ation methionine used. Cleavage was also supported by the immunofluorescense 
analyses showing that the signals of GFP and the C-terminal CLN5 antibody did not 
co-localise (Figure 9D and I; Figure 1D-E). GFP was always located in the ER 
whereas CLN5 was detected in the lysosomes in all M1-M4 constructs. Under endo-
genous circumstances signal sequences are rapidly degraded and therefore would be 
hard to detect. One possibility, why the sequence was detectable in the ER might be 
the GFP tag and/or the use of a transient overexpression system. 
The result that all M1-M4 CLN5 constructs are cleaved and result in the same size 
proteins is an important starting point for future studies. This needs to be taken into 
consideration e.g. when developing antibodies, probes etc. If only one or all of the 4 
possible initiation methionines are used in vivo remains elusive. 
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Figure 9: processing of human CLN5. (A) The human CLN5 protein contains four 
possible initiation methionines (M1-M4) at the following amino acid (aa) positions: 1, 
30, 50 and 62. A predicted cleavage site is at position 96. A GFP-tag was introduced in 
front of all possible initiation methionines M1-M4. The constructs were transiently 
transfected into HeLa and COS-1 cells. COS-1 lysates were analysed by SDS-PAGE 
followed by Western Blotting using (B) the novel C-terminal CLN5 antibody and (C) 
GFP antibody. (D) Transfected HeLa cells were immunostained with a CLN5 antibody 
(red) and LAMP-1 (blue) was used as a lysosomal marker. As examples, the constructs 
GFP.M1 and GFP.M4 are presented here. *unspecific band 
 
One pitfall is that the currently available antibodies against the CLN5 sequence do 
not recognise endogenous protein. Therefore, to study the maturation of the protein a 
stably human CLN5 expressing cell line starting from M1 (CLN5-SH-SY5Y) was 
established. Pulse-chase experiments and treatments of the stable cell line with re-
agents that affect normal protein transport namely cycloheximide (chx), tunicamycin 
and brefeldin A (BFA) revealed the existence of a 60 kDa pro- and a 50 kDa mature 
form of CLN5 (I; Figure 2 A-C, F). Chx blocks the de novo protein synthesis in-
hibiting translation elongation through binding to the E-site of the 60S ribosome and 
then blocks eEF2-mediated tRNA translocation (Schneider-Poetsch et al., 2010). 
Occupation of the E-site by CHX and deacetylated tRNA causes an arrest of the 
ribosome on the second codon. BFA inhibits anterograde trafficking between the ER 
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and Golgi apparatus. This compound is often used to study protein trafficking in the 
endomembrane system of mammalian cells and it intervenes with the recruitment of 
coat proteins (COPI), which are important for certain vesicle formations (Nebenfuhr 
et al., 2002). Treatment of cells with BFA leads to loss of COPI coats from the 
Golgi apparatus and subsequently anterograde vesicles are not longer able to fuse 
with the maturing cis cisterna of the Golgi. Tunicamycin is commonly used to study 
protein N-glycosylation, which blocks the synthesis of dolichol pyrophosphate-N-
acetylglucosamine, a key enzyme in glycoprotein biosynthesis in the ER from the 
start (Elbein, 1987). 
Moreover, the glycosylation status of CLN5 was verified and validated that it is 
highly glycosylated containing high mannose and complex type sugars (I; Figure 2 
D-F). BFA treatment and subsequent analysis by Western Blotting indicated that the 
mature 50 kDa form of CLN5 derives from the 60 kDa proform by trimming of the 
carbohydrate trees. This possibly takes place in the TGN or post-Golgi (see over-
view Figure 10). 
The most common route for soluble lysosomal proteins to lysosomes is the MPR- 
mediated pathway, which has also been suggested for CLN5 by proteomic analyses 
(Kollmann et al., 2005; Sleat et al., 2006). Biochemical testing if CLN5 comes in 
the cytosolic or membrane fraction from human patient fibroblasts has been per-
formed with the use of an antibody which was thought to detect endogenous CLN5 
protein (Bessa et al., 2006). However, the same antibody was tested in this study and 
previous results were not reproducible in our cell systems, indicating either that the 
antibody was unspecific for CLN5 in Western Blot analysis or detected yet unknown 
splice variants. Cell biological experiments to analyse the trafficking of CLN5 has 
not been performed prior to this study. Transient transfections of MPR-deficient 
fibroblasts indicated that CLN5 is also able to use an alternative route as im-
munofluorescence studies revealed lysosomal distribution within these cells (I; Fig-
ure 3). Which alternative route this may be, needs to be studied further, e.g. through 
LIMP-2 or sortilin. Interestingly, another NCL member CLN10/Cathepsin D has 
been described to be able to use the classical MPR-dependent pathway and also the 
sortilin mediated route to traffic to lysosomes (Canuel et al., 2008). The finding that 
CLN5 is highly N-glycosylated and also secreted into the culture medium further 
pinpoints to a soluble protein (Isosomppi et al., 2002; unpublished). 
In summary, this study was important to elucidate some basic information about the 
CLN5 protein (see overview Figure 9). The earlier discrepancies, whether CLN5 is 
an ER or a lysosomal protein, could be clarified.  
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5.1.3 Consequences of mutations on the cellular localisation of CLN5 (I) 
Next, it was of interest how different disease-causing mutations may affect the traf-
ficking of CLN5 towards lysosomes. To investigate this, several cell lines as HeLa 
(for IF studies) and COS-1 (for Western Blot analyses) cells were each transiently 
transfected with constructs carrying five different mutations (see Table 7).  
 
 
Table 7: list of CLN5 mutations analysed in transiently transfected cell lines and 
their intracellular localisation at steady-state and after treatment with cyclohexi-
mide (chx) for 6h. 
 
The intracellular localisation of mutated constructs carrying p.R112P and p.R112H 
has not been characterised prior to this thesis project. The amino acid 112 has been 
found to be mutated in a Portuguese family (p.R112P) and a Colombian patient 
(p.R112H). The Colombian patient presented a juvenile onset of the CLN5 disease 
at the age of nine years with visual loss and fast disease progression (Pineda-Trujillo 
et al., 2005). The Portuguese patient is a compound heterozygous (null mutation 
p.Q189X in one allele, mutations p.D279N and p.R112P in the other allele) present-
ing late infantile onset (Bessa et al., 2006). The mutations p.E253X and p.D279N 
have been reported prior to this study but the intracellular localisation of mutated 
protein containing the p.E253X mutation has not been examined (Holmberg et al., 
2000; Savukoski et al., 1998; Vesa et al., 2002). The mutation p.Y392X was in-
cluded because the localisation of the mutated protein remained controversial (Iso-
somppi et al., 2002; Savukoski et al., 1998; Vesa et al., 2002).  
At steady-state, all mutations lead to ER retention of the expressed CLN5 in HeLa 
cells (I; Figure 4, Supp. Figure S2). It has been published earlier that constructs 
carrying the mutations p.D279N and the most common mutation in Finland 
p.Y392X were able to reach the Golgi and even lysosomes (Isosomppi et al., 2002; 
Vesa et al., 2002). Therefore, the transiently transfected HeLa cells were treated 
with chx, to block the protein synthesis and chased the mutated CLN5 proteins up to 
5h (I; Figure 5). Under these conditions, proteins with the missense mutations 
p.R112H and p.R112P did not leave the ER and were stably detected in the ER. The 
ER retention is probably due to folding defects caused by the mutations. It would be 
Amino acid change Mutation Steady-state localisation 
Localisation after 5h 
of chx treatment 
p.R112P missense ER ER 
p.R112H missense ER ER 
p.E253X early stop ER unstable 
p.D279N missense ER ER, partly lysosomal 
p.Y392X 2-bp deletion ER unstable 
5 Results and discussion 
 
THL — Research 84/2012 69 The CLN5 disease - protein  maturation, trafficking and pathology 
 
important to investigate the role of CLN5 mutations in ER-stress mediated apoptotic 
cell death and ER-quality control. ER-stress responses have been shown to contri-
bute to the disease progression in other NCLs, like CLN1/PPT1, CLN6 and CLN8 
(Galizzi et al., 2011; Oresic et al., 2009; Wei et al., 2008). 
As expected, proteins carrying the mutation p.D279N were able to reach lysosomes. 
This construct contained a mutation that resulted in an additional N-glycosylation 
site.The proteins with an early stop (p.Y392X, p.E253X) were unstable and not 
detectable after 5h chx treatment. At shorter incubation times (1h) the mutated pro-
teins were mostly detectable in the ER and in few cells detectable in vesicular struc-
tures, which however did not co-localise with the lysosomal marker LAMP-1. Iso-
somppi et al. utilised transiently transfected BHK-21 cells with CLN5 construct 
carrying the mutation p.Y392X and reported co-localisation with the medial Golgi 
marker CTR433 in most cells, partly ER and some vesicular-like staining (not co-
localising with a lysosomal marker lgp120) at steady-state (Isosomppi et al., 2002). 
The slight differences in detected localisation of the same mutant protein are poten-
tially explainable by the use of different cell lines. Consistent with the data pre-
sented in this thesis work it was reported that 1 h chx treatment of transiently trans-
fected BHK-21 cells resulted in decreased staining. Only minor vesicular staining 
was observed, which did not co-localise with lysosomal markers. Also, longer chx 
treatments led to total loss of staining, indicating instability of the mutated protein 
(Isosomppi et al., 2002).  
To assess whether the glycosylation status of the mutated CLN5 constructs p.R112H, 
p.R112P and p.D279N support the detected localisation, transiently transfected 
COS-1 cell lysates were treated with EndoH and PNGaseF, digesting the high man-
nose and complex type sugars, respectively. Interestingly, Western Blot analysis 
revealed that the CLN5 proteins carrying the mutations p.R112H and p.R112P con-
tained both high mannose and complex type sugars even though immunofluores-
cence studies pinpointed to stable ER retention. This lead us to the conclusion that 
the CLN5 protein is able to traffic to the Golgi, where complex type sugars are 
added, and return to the ER after maturation and possibly interact with other proteins. 
This might be important since in vitro studies have shown that CLN5 interacts with 
other NCL proteins such as CLN1-3, 6 and 8 (Lyly et al., 2009; Vesa et al., 2002). 
CLN6 and CLN8 are ER-resident proteins and it has been previously reported that 
CLN8 can recycle between ER and the ER-Golgi intermediate compartment (Lonka 
et al., 2000). Therefore, CLN8 might interact with CLN5 within the pathway either 
from the ER towards the Golgi or in the recycling pathway from the Golgi towards 
the ER.  
The majority of CLN5 mutations cause a late infantile variant phenotype with very 
small variation in the clinical phenotype. For example, patients with CLN5 muta-
5 Results and discussion 
 
THL — Research 84/2012 70 The CLN5 disease - protein  maturation, trafficking and pathology 
 
tions carrying p.Y392X, p.Y75X, p.D279N and p.W224LfsX30 present the typical 
disease progression, even though the consequences on protein level have been 
shown to be very different in vitro (ER retention and lysosomal distribution, see 
Table 7). Also, the Portuguese patient carrying two CLN5 mutations (p.D279N and 
p.R112P) presented classical disease onset and progression. As CLN5 carrying 
p.D279N alone was capable to rearch lysosomes at some point, it is likely that 
p.R112P affects the protein more severely. However, the Colombian patient with the 
mutation p.R112H presented a milder phenotype, which might indicate that the 
change from arginine to histidine may disrupt the function to a lesser extent than the 
change to proline. Nevertheless, this cannot be stated for sure as the Portuguese also 
carried the p.D279N mutation in one allele. It has been shown that Cln1 expression 
is increased in Cln5 ko mice and that CLN1 wt protein was able to rescue the lyso-
somal trafficking of CLN5 carrying different disease mutations in overexpression 
studies in vitro. This indicates a compensatory role of CLN1/PPT1 in Cln5-
deficiency. This might be the reason why p.R112H mutated proteins were restricted 
to the ER in transient overexpression studies as endogenous CLN1/PPT1 expression 
may not be able to compensate the overexpressed levels (will be discussed later). 
Overall, Figure 10 summarises the suggested maturation of the CLN5 protein 
(5.1.1-5.1.3). 
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Figure 10: summary of the predicted maturation of the CLN5 protein: 1. In the ER 
the signal peptide is removed from the pre-proform of CLN5. 2. Next, high mannose-
type residues are added. 3. CLN5 continues to the Golgi where complex-type sugars are 
added. 4. Possible retrograde transport back to the ER. 5. CLN5 may interact with other 
proteins such as CLN6, 8 and 1. 6. CLN5 continues through the early secretory pathway 
and traffics to the lysosomes via MPRs or 7. uses an alternative unknown route to the 
lysosomes.  
Abbreviations: CGN, cis Golgi network; ER, endoplasmic reticulum, N, nucleus; TGN, 
trans Golgi network. Some elements of the figure were produced using Servier Medical 
Art (www.servier.com). 
5.2 Pathology of Cln5 in mice (II) 
5.2.1 Loss of Cln5 leads to early inflammation and defective 
myelination in the mouse brain (II) 
Preceding this thesis, Cln5 ko mice had been generated and some basic characterist-
ics have been studied (Kopra et al., 2004; von Schantz et al., 2009; von Schantz et 
al., 2008). It has been reported that in Cln5 ko mice cortical neuron loss was present 
at the age of 4 months, reactive astrocytosis at 1 month and microglial activation at 
12 months (von Schantz et al., 2009). Myelination defects in these mice were sug-
gested due to findings of gene expression arrays but this has not been verified fur-
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ther prior to this thesis work (Kopra et al., 2004; von Schantz et al., 2008). One aim 
of this thesis project was to further characterise the pathology of Cln5 ko mice fo-
cusing on the early stage of the disease. Hence, 1 and 3 months old Cln5 ko mice 
were used in our studies. Two regions were exemplarily examined, the ventral pos-
terior nuclei of the thalamus (VPM/VPL) and the somatosensory barrel field cortex 
(S1BF; sends and receives information from the VPM/VPL region), as these are 
regions known to be affected in Cln5 ko mice in general (von Schantz et al., 2009). 
Furthermore, as representative white matter structures the corpus callosum (cc) and 
internal capsule (ic) were analysed (Figure 11). 
 
 
 
Figure 11: schematic coronal view of the mouse brain regions focused on in study II 
+ III. The brain regions which were analysed the most are highlighted in grey. White 
matter structures: corpus callosum (cc) and internal capsule (ic). Somatosensory barrel 
field cortex (S1BF) sends/receives information to/from the ventral posterior nuclei of the 
thalamus (VPM/VPL). Modified from The Mouse Brain in Stereotaxic Coordinates 
(Paxinos and Franklin, 2001).  
 
The finding that the highest Cln5 expression levels were found in microglia indi-
cated a possible important role for Cln5 in these cells, which are important key play-
ers of the immune system in the CNS. The study of the microglial activation marker 
F4/80 indicated earlier that microglial activation would not take place before 12 
months of age (von Schantz et al., 2009). In contrast, in this thesis project the 
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microglial markers CD68 and IBA-1 indicated significant activation already at the 
age of 3 months in the studied regions S1BF and VPM/VPL (Figure 12 and II; 
Figure 2). Microglial activation in 1 month old mice was not significant yet but 
showed trends towards activation. IBA-1 stained cells also presented changes in 
morphology from the branched resting state towards an amoeboid active state in 3 
months old Cln5 ko mice compared to wt controls (Figure 5 and II; Figure 2). 
Unbiased thresholding image analysis of CD68 stained mouse brain sections verified 
the observations (II; Figure 3). The microglial activation was not confined to these 
regions but was widespread throughout the CNS, being most evident in other tha-
lamic relay nuclei and cortical regions (somatosensory and auditory) as well as in 
the subiculum and substantia nigra. This, together with the finding that Cln5 expres-
sion was enhanced in primary cultured microglia upon LPS induction, encouraged 
us to assess whether the immune response is altered in primary cultured microglia. 
LPS has been shown to trigger the expression of inflammatory mediators like inter-
leukin 1 (IL-1), IL-6, reactive oxygen species (ROS), nitric oxide (NO) and tumor 
necrosis factor α (TNFα) in several cell types including microglia (Block et al., 2007; 
Suzumura et al., 2006). Therefore, the cytokine secretion from Cln5 ko microglia 
was measured with and without LPS stimulation and compared to wt secretion pro-
files. However, no significant changes were detected between Cln5 ko and wt 
microglia when 40 different cytokines were analysed (II; suppl. Figure 1). These 
results suggest that Cln5 expression is upregulated in response to inflammatory 
stimuli (II; Figure 1C) but has no influence on the inflammatory response itself. 
However, further studies are required to assess whether the upregulated Cln5 gene 
expression reflects Cln5 protein levels. Further, it would be of interest to analyse if 
purified Cln5 protein has an effect on microglial cells.  
The circumstances defining whether microglial activation is harmful or beneficial to 
neuronal survival remain largely unclear. Microglial activation seems to be crucial 
for host defence and neuron survival, but overactivation of microglia causes destruc-
tive and neurotoxic consequences (Block et al., 2007). The link between LPS stimu-
lation and enhanced Cln5 expression remains to be solved. 
Next, possible myelination defects suggested by previous gene expression analyses 
and MRI studies in patients were investigated (Holmberg et al., 2000; Kopra et al., 
2004; Rapola et al., 1999; von Schantz et al., 2008). Therefore, the volumes of white 
matter structures of the corpus callosum (cc) and internal capsule (ic) from Nissl 
stained brain sections from 1 and 3 month old Cln5 ko and wt mice were quantified 
but did not indicate any significant changes at these ages. Myelin basic protein 
(MBP) was used as a marker to investigate the overall myelination within the brain. 
No alterations in white matter structures were observed but clearly disturbances in 
the myelination in the superficial laminae of the cortical region S1BF at the age 1 
and 3 months of age were observed (Figure 12 and II; Figure 4, suppl. Figure 2). 
5 Results and discussion 
 
THL — Research 84/2012 74 The CLN5 disease - protein  maturation, trafficking and pathology 
 
Unexpectedly, LFB staining showed less staining in white matter structures in Cln5 
ko mice, but this could reflect the lipid metabolism changes in the knockout mice 
(discussed in detail later) as LFB is bound by lipids (II; suppl. Figure 3).  
 
 
 
Figure 12: overview of the pathologic patterns taking place in young Cln5 ko mice 
at 1 and 3 months of age. On the left a simplified normal organisation of thalamocorti-
cal pathways between the S1BF and VPM/VPL regions are presented. Sensory afferents 
reach thalamic relay neurons, which project mainly to lamina IV granule neurons. In turn, 
cortico-thalamic feedback neurons are mostly located in lamina VI. No neuron loss was 
detected in 3 month old in Cln5 ko mice (III) and therefore no loss is predicted for 1 
month old Cln5 ko mice. Microglial activation is slightly elevated in 1 month old Cln5 
ko mice and is significant at 3 months of age (II). Activated microglia are found more 
prominent in the thalamic region at these age points compared to the cortex. Reactive 
astrocytosis has been detected in both regions of 1 month old Cln5 ko mice, but these 
mice were in a different background (in brakets; von Schantz et al., 2009). Herein, 3 
month old Cln5 ko mice were tested and presented reactive astrocytosis in the S1BF and 
VPM/VPL region (III). Significant defective myelination was detected in both age 
points in the superficial laminae of the S1BF region, but not in white matter structures 
(II). 
 
In vitro differentiation studies of neurospheres towards mature oligodendrocytes by 
growth factors revealed a clearly delayed differention in Cln5 ko cells supporting the 
suggestion of defective myelination in oligodendrocytes (II, Figure 5). Oligoden-
drocyte precursor cells (OPCs) were proliferated and differentiated towards mature 
myelinating oligodendrocytes (see Figure 4). In the early stages (4 days differenti-
ation conditions) no differences in the morphology of NG-2 positive cells were ob-
served in Cln5 ko cells compared to wt OPCs. At later stages (7-10 days differenti-
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ation conditions) MBP immunostaining presented differences in morphology. MBP 
specifically stains differentiated oligodendrocytes, but in contrast to the large flat-
tened shape in wt OLs, Cln5 ko OLs displayed numerous ramified processes and a 
small cell soma (II; Figure 5). 
In the light of these results it is likely that the decreased MBP staining in the cortex 
of Cln5 ko mice is due to a defective myelination process or is reflecting loss of pre-
existing myelin. The number of neurons is not affected in 3 month old Cln5 ko mice 
in the S1BF and VPM/VPL region (Figure 12 and III; Figure 5) supporting the 
hypothesis that there may be a defect in OLs themselves as lack of MBP staining 
does not reflect neuron loss. Also, the in vitro studies pinpoint towards defects in the 
OLs. Prior to this thesis, reactive astrocytosis has been detected in 1 month old Cln5 
ko mice of different background than studied here (von Schantz et al., 2009). Herein, 
3 month old Cln5 ko mice were analysed and reactive astrocytosis was also detected 
at this age point (Figure 12 and III; Figure 3). Therefore, it will be interesting to 
examine if these two events are linked to each other as reactive astrocytosis has been 
connected to support remyelination (Shields et al., 2000; Talbott et al., 2005). 
Astrocytes secrete various factors which have been shown to coordinate complex 
responses by other cell types (Moore et al., 2010). Among these secreted factors are 
platelet-derived growth factors (PDGF), which have been reported to influence oli-
godendrogenesis as the PDGF-α receptor is a phenotypic marker for OPCs (Moore 
et al., 2010). PDGF-α expression has been presented to lead to increased OPC pro-
liferation following focal demyelinating lesions (Vana et al., 2007; Woodruff et al., 
2004). Also, conditioned media of astrocytes has been shown to increase oligoden-
drocyte differentiation (Moore et al., 2010). Hence, astrocytes may promote myelin 
repair by e.g. PDGF-related signalling in the early stages of CLN5 disease, and pos-
sibly other NCL diseases until the capacity to repair the damages is reduced by time. 
Another interesting aspect for future studies is the interplay between microglia and 
astrocytes. Pro-inflammatory factors released by activated microglia have been 
shown to trigger reactive astrocytosis and inhibition of microglia resulted in sup-
pressed reactive astrocytosis (Zhang et al., 2010). Therefore, it would be interesting 
to study whether the inhibition of microglia has an effect on the pathology of Cln5 
ko mice. 
In conclusion, loss of functional Cln5 leads to widespread early inflammation in the 
CNS (microglial activation and reactive astrocytosis) and defective myelination 
preceding neuronal degeneration. These findings give valuable information about 
the timing of pathological events in Cln5 ko mice and point out the necessity to 
study the interplay between different cell types of the CNS in CLN5 disease.  
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5.2.2 Cln5 ko mice present disturbances in systemic lipid metabolism (II) 
Alterations in lipid metabolism has been linked to many neurodegenerative diseases, 
including NCLs (Ahtiainen et al., 2007; Haidar et al., 2006; Jalanko et al., 2006; 
Lyly et al., 2008; Lyly et al., 2009; Narayan et al., 2006; Winter and Ponting, 2002) 
(see 2.4.2). Dysregulated cholesterol metabolism has been linked to Cln1 ko mice 
(Lyly et al., 2008) (see 2.4.2). Further, sphingolipid metabolism was shown to be 
affected in NCLs. It was demonstrated that Cln10 ko mice displayed increased lev-
els of several gangliosides, molecules composed of a glycosphingolipid containing 
one or more sialic acids connected to the sugar chain, especially monosialogan-
gliosides (GM2, GM3 and GD3) and bis(monoacylglycero)-phosphate (BMP) in the 
mouse brain were increased (Jabs et al., 2008). It was further specified that GM2 
was mainly accumulated in neurons and GM3 increased in glial cells (Jabs et al., 
2008). Recently, a review pointed out that human CLN9-deficient fibroblasts [the 
putative gene affected in CLN9 disease] contained lower amounts of ceramide and 
decreased ceramide synthase activity (Ben-David and Futerman, 2010). Overexpres-
sion of ceramide synthase was shown to partially rescue the phenotype, suggesting a 
possible regulative role of CLN9 for the ceramide synthase (Ben-David and Futer-
man, 2010). 
To obtain insights whether the lipid homeostasis might be altered in general in Cln5 
ko mice, major lipid parameters from mouse serum derived from 1 month old mice 
were studied and the transport of cholesterol and sphingolipids in macrophages was 
analysed (II; Figure 6-7). Total cholesterol levels and phospholipid transfer protein 
(PLTP) activity were significantly increased in Cln5 ko mice compared to wt mice, 
whereas no differences in triglyceride and apoA-I levels were observed (see 4.1.18 
and II for methods and Figure 6). Further, fractionation by FPLC revealed that 
cholesterol was mainly found in HDL particles (II; Figure 6). Increased PLTP ac-
tivity in Cln5 ko serum supported this finding since PLTP has been reported to play 
a role in the transfer of cholesterol and phospholipids from cells to lipoprotein parti-
cles by interaction with ABCA1 (Oram et al., 2003). Further, increased cholesterol 
transfer to apolipoproteins was verified by cell studies. Cholesterol efflux from peri-
toneal macrophages towards the major apolipoprotein of HDL, apoA-I, was signifi-
cantly increased in Cln5 ko compared to wt cells (II; Figure 7), whereas the uptake 
of cholesterol was similar in Cln5 ko and wt peritoneal macrophages. 
It has been reported earlier that CLN1/PPT1, CLN5 and the mitochondrial F1-
ATPase synthase interact in vitro (Lyly et al., 2008; Lyly et al., 2009) and the latter 
has been shown to act as a receptor for apoA-I (Martinez et al., 2003). Further, some 
NCL models display mitochondrial alterations (Das et al., 1999; Fossale et al., 2004; 
Lyly et al., 2008; Siakotos et al., 1998). The cell surface distribution of the α- and β-
subunits of the mitochondrial ATP synthase has been shown to be increased in Cln1 
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ko neurons detected by total internal reflection fluorescence (TIRF) microscopy 
(Lyly et al., 2008). Correspondingly, apoA-1 uptake has been presented to be in-
creased in Cln1 ko neurons. Herein, the cell surface distribution of α- and β-subunits 
of the mitochondrial ATP synthase was also analysed by TIRF analysis in Cln5 ko 
neurons but no changes were detected compared to wt neurons. This indicates that 
the possible defect in CLN5, linked to ATP synthase is not analogous to CLN1 dis-
ease. In conclusion, serum lipid analyses pinpoint to opposite roles in lipid metabo-
lism for Cln1 and Cln5. Table 8 summarises the general findings in Cln1 ko and 
Cln5 ko mice.  
 
Wt vs. Mouse model Cln1 ko Cln5 ko 
PLTP activity ↓ ↑ 
Total cholesterol ↓ ↑ 
ApoA-I ↓ - 
Cell surface distribution of the α/β 
SU of the mF1-ATPase in neurons 
↑ - 
Triglycerides - - 
ApoA-I uptake ↑ (in neurons+glia) - (in macrophages) 
ApoA-I efflux n.d. ↑ (in macrophages) 
Cholesterol increased in n.d. HDL 
 
Table 8: overview of the detected changes in serum lipid analyses and cell studies in 
Cln1 ko (Lyly et al., 2008) and in Cln5 ko mouse (study II) models compared to wt 
mice. Abbreviations: n.d., not determined; α/β SU of mF1-ATPase, α/β subunits of the 
mitochondrial F1-ATPase. 
 
In this study, sphingolipid transport was also shown to be affected in peritoneal 
macrophages and MEFs of Cln5 ko mice. Fluorescent glycosphingolipid BODIPY-
Lactoceramide was transported slower from endo-lysosomes to the Golgi apparatus 
compared to wt cells (see 4.1.18 and II; Figure 8). This is characteristic for sphin-
golipid storage diseases and therefore indicates that CLN5 disease may also display 
features of sphingolipidoses. It is noteworthy that sphingolipids are especially en-
riched in the myelin sheath and important for maintaining myelin in the CNS (Pic-
cinini et al., 2010). Hence, the altered sphingolipid transport and the defective my-
elination may be connected, which will be interesting to study in the future. This 
finding also suggests that CLN5 protein may be involved in lipid transport or their 
signalling pathways. As described in the literature review in chapter 2.3.1 ABC 
transporters are important key players in cholesterol efflux to the extracellular space 
and have been reported to be connected to another NCL protein, namely 
CLN10/Cathepsin D (Haidar et al., 2006). The study of Haidar et al., reported that 
reduction of CLN10/Cathepsin D leads to reduced ABCA1 levels and consequently 
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to decreased cholesterol efflux. In addition, ABCA1 is known to be higly expressed 
in microglia and ABCA2 has been reported to mediate intracellular shingolipid 
transport and myelin maturation (Kim et al., 2008). It would be of high interest to 
investigate whether these transporters are also affected in CLN5 disease. 
5.3 CLN5 and its interaction partner CLN1/PPT1 (III + unpubl.) 
5.3.1 CLN1/PPT1 rescues the trafficking of mutated CLN5 to the 
lysosomes (unpublished) 
Interactions between CLN5 and other NCL proteins have been suggested previously 
in vitro, including CLN1/PPT1, CLN2/TPP1, CLN3, 6 and 8 (Lyly et al., 2009; 
Vesa et al., 2002). Our group has previously shown that the lysosomal localisation 
of CLN5 carrying the most common disease-causing mutation, p.Y392X, can be 
restored by co-expressing wt CLN1/PPT1 supporting interactions between these two 
proteins (Lyly et al., 2009). In contrast, co-expression of the mutated CLN5 protein 
with other NCL proteins did not result in correction of the lysosomal trafficking 
(Lyly et al., 2009). Based on this finding, the study of this interaction was expanded 
in order to investigate whether PPT1 could restore the trafficking of CLN5 proteins 
carrying different disease-causing mutations. Therefore, PPT1 was transiently over-
expressed with mutated CLN5 constructs carrying p.D279N or p.E253X in SH-
SY5Y cells. The impact of PPT1 on the trafficking of the mutated CLN5 proteins 
was analysed by confocal microscopy and LAMP-1 was used as a lysosomal marker 
(Figure 13 C,G,K,O,S,W). Single transfection of the mutated CLN5 constructs lead 
to ER retention in SH-SY5Y cells (Figure 13 I-L, Q-T), but co-transfection with wt 
PPT1 dramatically changed the intracellular localisation of the mutated CLN5 pro-
teins from ER retention towards vesicular distribution and co-localised with PPT1 
and the lysosomal marker LAMP-1. It is noteworthy that mutated CLN5 had no 
effect on the intracellular localisation of PPT1. 
These results indicate that the folding of the analysed mutated CLN5 proteins is 
probably not that severely affected due to the fact that PPT1 is still able to bind to 
the mutated CLN5 proteins and they can traffic to the lysosomes. The mutations 
possibly hit amino acids important for the function of CLN5 or disturbing other 
important interactions of the protein. However, the molecular basis of the interaction 
between these two NCL proteins remains elusive at this point. It could be speculated 
that PPT1 might act as a chaperone or is somehow facilitating the trafficking of 
CLN5 protein. This is interesting in particular as CLN5 was still able to traffic to 
lysosomes in MPR-deficient cells, indicating that CLN5 can utilise MPR-
independent routes to reach lysosomes (I; Figure 3). It has been reported earlier that 
also PPT1 itself behaved differently from classical soluble lysosomal enzymes 
which utilise the MPR-dependent pathway (Lyly et al., 2007). Mutating the glycosy-
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lation site that was mostly involved in the MPR receptor binding did not affect the 
localisation of PPT1 in vitro. 
 
  
 
 
Figure 13: Rescued trafficking of mutant CLN5 by co-expression with wild-type (wt) 
CLN1/PPT1. SH-SY5Y cells were either transiently transfected alone with wt CLN5 
(A-H), CLN5 carrying the p.D279N (I-P), p.E253X (Q-X) mutations or co-transfected 
with wt CLN1/PPT1 (E-H, M-P, U-X). Localisation of wt and mutant CLN5 protein was 
accessed through immunofluorescence with triple-staining for CLN5 (A,E,I,M,Q,U), 
CLN1/PPT1 (B,F,J,N,R,V), and lysosomal marker LAMP-1 (C,G,K,O,S,W). Stained 
cells were analysed by confocal microscopy and co-localisation is indicated by: CLN5 
and LAMP-1 – pink; CLN5 and CLN1/PPT1 - yellow; CLN5, CLN1/PPT1 and LAMP-1 
–white 
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5.3.2 Basic characterisation of Cln1/5 dko mice (III) 
Since in vitro studies and gene expression profiling of knockout mouse models 
have linked the NCL proteins PPT1 and CLN5 and suggest common pathogenic 
mechanisms, our aim was to further study the putative common pathways by 
generating a Cln1/5 double knockout (Cln1/5 dko) mouse (see 4.1.1) and to 
analyse its basic pathology. It could be expected that if CLN1 and CLN5 share 
common pathways, a knockout of both genes would result in a very severe dis-
ease. The double knockout mice were fertile but displayed a slight reduction in 
Mendelian breeding ratios (III; suppl. Table 1). The decreased number of ex-
pected offspring indicated possible defects in breeding or early development of 
Cln1/5 dko mice. Previous studies with lysosomal storage disorders have indi-
cated dysregulated formation of embryoid bodies from induced pluripotent stem 
cells (iPS-cells) (Meng et al., 2010) and, therefore, iPS cells of wt and Cln1/5 
dko MEFs were generated. Morphologically selected clones, which also ex-
pressed the ES cell-specific markers SSEA-1; Nanog, Rex1, E-ras, Esg-1 and 
Fgf-4 (III; suppl. Figure 2) were chosen for embryoid body (EB) formation and 
further experiments. Microscopic follow up and diameter measurements re-
vealed significantly smaller and irregular formed Cln1/5 dko EBs compared to 
wt EBs up to 7 days (III; Figure 2). After 7 days Cln1/5 dko EBs seemed to 
catch up and differences became less prominent pinpointing to defects in early 
development of EBs. In addition, spontaneous differentiation was also delayed 
in Cln1/5 dko EBs (III; Figure 2). 
At the age of 3 months the Cln1/5 dko mice showed severe symptoms with bal-
ance problems and seizures (described in III) and the body weight was signifi-
cantly lower compared to wt mice (III; suppl. Figure 1). The onset of symp-
toms was way earlier than in the single knockout mice. For Cln1 ko mice, the 
onset of symptoms has been reported to be from 5 months onwards and for Cln5 
ko mice only after 8 months (Jalanko et al., 2005; Kopra et al., 2004). The ac-
cumulation of autofluorescent storage material of 3 month old mice was studied 
in wt, Cln1ko, Cln5 ko and Cln1/5 dko brains. It was highly prominent in Cln1/5 
dko, a bit less in Cln1 ko mice and almost absent in Cln5 ko and wt mice (III; 
Figure 1). The ultrastructure of the storage material in 3 month old Cln1/5 dko 
mice was analysed by electron microscopy and displayed mainly GRODs and 
few rectilinear-like membranous ultrastructures (III; Figure 1). Further, peri-
odic acid Schiff (PAS) staining revealed storage material in cortical neurons and 
glia in Cln1/5 dko mice, but not in single-knockout or wt mice (described in III; 
data not shown). 
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5.3.3 Glial activation and defective myelination precedes neuron loss 
Cln1/5 dko mice (III) 
Since early immune activation, such as microglial activation and astrocytosis has 
been observed in Cln1 ko and Cln5 ko mice (Bible et al., 2004; von Schantz et 
al., 2009) (see 5.2.1), the glial activation was also studied in Cln1/5 dko mice 
and was compared to the single-knockout and wt mouse brains focusing on the 
S1BF and VPM/VPL as representative regions (see Figure 11). 
The extent of microglial activation was detected with a CD68 marker in immu-
nohistochemical analyses. CD68 detected significant microglial activation in 
Cln5 ko mice at the age of 3 months (II; Figure 2+3). Therefore, 3 month old 
mice were selected for the analyses. Importantly, the CD68 marker had not been 
used in immunohistochemical studies for Cln1 ko mice so far. At the age of 3 
months all three knockout mouse models presented widespread immunoreac-
tivity, most prominent again in Cln1/5 dko mice, then Cln1 ko and less in Cln5 
ko (Figure 14 and III; Figure 3). As the extent of immunoreactivity was very 
intense in 3 months old Cln1/5 dko mice, 1 month old Cln1/5 dko mouse brains 
were also stained and compared to wt mice revealing increased reactivity at this 
young age and further supporting the early microglial activation as an important 
phenotypic outcome of NCL (III; suppl. Figure 4).  
GFAP was used to detect the extent of reactive astrocytosis and immunohisto-
chemical staining revealed very intense immunoreactivity in Cln1/5 dko mice, 
strong in Cln1 ko, a few GFAP positive cells in Cln5 ko mice and almost none 
in wt mouse brains at the age of 3 months (Figure 14 and III; Figure 3). As the 
astrocytosis has been previously detected in the single ko mice already at 1 
month, it is very likely that also Cln1/5 dko mice display significant astrocytosis 
earlier than 3 months. 
In this study, defective myelination was presented to be a phenomenon linked to 
Cln5 ko mice (II; see 5.2.1), but this has not been previously studied in Cln1 ko 
mice, although human studies have earlier implicated demyelination in CLN1 
disease (Haltia et al., 1973a). As in study II, MBP was used to detect possible 
myelination defects. As previously seen in Cln5 ko mice, there were no clear 
differences in the MBP immunoreactivity in white matter structures. However, 
all three mouse models presented less MBP positive fibres (dorsoventrally and 
horizontally) through the superficial laminae of S1BF, most prominently again 
in the Cln1/5 dko mouse brains, followed by Cln1 ko and Cln5 ko mouse 
models (Figure 14 and III; Figure 4). Our studies thus implicate that cortical 
loss of MBP positive fibres is a prominent pathological feature of two NCL 
models and it will be interesting to investigate whether this is a common feature 
in NCLs. 
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Neuronal loss and brain atrophy was studied from Nissl stained sections. Thick-
ness and volume measurements of various brain regions were carried out to de-
termine possible mouse brain atrophies. No cortical thinning or volume alter-
ations were detected in Cln1/5 dko or Cln1 ko mice compared to wt control in 3 
months old mice, but a slight increase in thickness of the S1BF, M1 and V1 
region and cortical volume in Cln5 ko mice was measured (III; suppl. Figure 5). 
This supports earlier findings, where mice increased cortical thickness measures 
have also been reported in 12 month old Cln5 ko mice (von Schantz et al., 2009). 
This finding may be comparable to the hydrocephalus which has been observed 
in some NCL patients (Lee et al., 2003). 
Neuronal loss was determined by stereological measurements in Nissl stained 
sections of thalamic VPM/VPL and neuron populations in three cortical laminae 
of the S1BF region. Lamina IV granule neurons receive thalamic innervations, 
and lamina V and lamina VI contain projection neurons which provide important 
feedback to the thalamus. Significant cortical neuron loss in the S1BF region 
was only detected in lamina VI in 3 month old Cln1/5 dko mice, but not in the 
thalamic VPM/VPL regions (Figure 14 and III; Figure 5). In single-knockout 
mice the findings were different. In Cln1 ko mice, significant neuron loss was 
observed in thalamic VPM/VPL at the age of 5 months, and in cortical S1BF 
lamina IV at the age of 7 months (Kielar et al., 2007). In Cln5 ko mice, signifi-
cant neuron loss was detected in cortical S1BF lamina V at the age of 4 months, 
and in both thalamic VPM/VPL and cortical S1BF laminae IV and V at the age 
of 12 months, but no significant loss of neurons was observed in S1BF lamina 
VI (von Schantz et al., 2009). Neuron loss in Cln1 ko mice begins in the thala-
mus and subsequently occurs in the cortical region, whereas the sequence is 
opposite in Cln5 ko mice and starts in the cortex. Therefore, neuron loss in 
Cln1/5 dko resembles more the Cln5 deficiency in a way that the loss starts from 
cortex. However, in Cln1/5 dko mice the neuronal loss starts from S1BF lamina 
VI and in Cln5 in lamina V. 
Pathological findings in Cln1/5 dko compared to Cln1 ko and Cln5 ko mice at 
the age of 3 months are summarised in Figure 14. The main result from these 
analyses is the conclusion that glial activation and defective myelination precede 
neuronal loss in these NCL mouse models, which has also been observed in 
Cln3 ko mice and Cln6 ko sheep and may a common feature in NCLs (Oswald 
et al., 2005; Pontikis et al., 2004; Pontikis et al., 2005). 
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Figure 14: overview of the pathologic patterns in 3 month old Cln5 ko, Cln1 ko  
and Cln1/5 dko mice. The schemes of the different mouse models are displayed 
from left to right according to the severity of pathologic findings. A simplified or-
ganisation of thalamocortical pathways between the S1BF and VPM/VPL regions is 
displayed. Sensory afferents extend to thalamic relay neurons, which project mainly 
to lamina IV granule neurons. In turn, cortical feedback neurons are found in lamina 
VI and project towards the thalamus. No neuron loss was detected in 3 month old 
neither in Cln5 ko nor Cln1 ko mice. In contrast, Lamina VI presented significant 
neuron loss in 3 month old Cln1/5 dko mice. Microglial activation is present in all 
knockout models and most prominent in Cln1/5 dko mice. In Cln5 ko mice activated 
microglia are more prominent in the thalamus than in the cortex, which is also the 
case for Cln1 ko mice. Reactive astrocytosis is present in all knockout mouse mod-
els and highly pronounced in the thalamus in Cln1 ko and Cln1/5 dko mice. Further, 
significant defective myelination was detected in the superficial laminae of the S1BF 
region in all knockout mouse models again being most prominent in Cln1/5 dko 
mice. 
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5.3.4 Dysfunctional lipid metabolism is a common feature in Cln1 ko, 
Cln5 ko and Cln1/5 dko mice (I+III) 
Disturbed systemic lipid metabolism has been detected for both single knockout 
mouse models, Cln1 ko (Lyly et al., 2008) and Cln5 ko (II; Figure 6-8; see 
chapter 5.2.2). Therefore, one aim of this thesis was to examine how the sys-
temic lipid metabolism changes when both genes Cln1 and Cln5 are simulta-
neously deleted. The levels of total cholesterol, phospholipids, apoA-1, triglyc-
erides, and PLTP activity in 1 month old female mouse serum were analysed 
(Table 9). The amounts of phospholipid and triglycerides in Cln1/5 dko mice 
were significantly increased compared to the wt control (III; Figure 6). Interest-
ingly, PLTP activity was highly and significantly elevated in Cln1/5 dko mice 
compared to wt mice (Table 9 and III; Figure 6), exceeding the previously 
observed increase in Cln5 ko serum (Table 8 and II; Figure 6; see chapter 
5.2.2). Total cholesterol levels were slightly increased but not significantly un-
like in Cln5 ko samples. The detected changes in phospholipid and cholesterol 
levels can be linked to the increased PLTP activity, as PLTP has been shown to 
maintain HDL cholesterol levels in serum (Zannis et al., 2008). Therefore, the 
distribution of lipids and apoA-1 in lipoprotein fractions was analysed in Cln1/5 
dko and wt serum. As previously shown herein, cholesterol was found to be 
clearly increased in HDL particles in Cln1/5 dko serum (Table 9 and III; suppl. 
Figure 6). In addition, cholesterol levels were slightly decreased in VLDL parti-
cles (III; suppl. Figure 6). Also, the amount of phospholipids and apoA-1 were 
clearly elevated in both small and large HDL particles (Table 9 and III; suppl. 
Figure 6). These findings might relate to the increased PLTP activity seen in 
Cln1/5 dko mice, as PLTP induces the formation of lipid-poor pre-β-migrating 
HDL particles (Vikstedt et al., 2007). Further, elevated triglyceride levels were 
found in VLDL particles (Table 9 and III; suppl. Figure 6).  
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Wt vs. mouse model Cln1 ko Cln5 ko Cln1/5 dko 
PLTP activity ↓ ↑ ↑↑ 
Total cholesterol ↓ ↑ - 
ApoA-I ↓ - - 
Triglycerides - - ↑ 
Phospholipids n.d. n.d. ↑ 
Cholesterol increased in n.d. HDL HDL 
ApoA-I increased in n.d. n.d. HDL 
Triglycerides increased in n.d. n.d. VLDL 
Phospholipids increased in n.d. - HDL 
 
Table 9: overview of the detected changes in serum lipid analyses of 1 month old 
Cln1 ko, Cln5 ko and Cln1/5 dko mice compared to wt. 
 
 
In summary, these results verify that lipid homeostasis is disturbed in NCL 
mouse models outside the CNS. It is most likely that this is also the case in the 
CNS, as disturbed lipid metabolism has been linked to neurodegeneration in 
general. Cholesterol is known to be present in the myelin sheath and, therefore 
disturbed cholesterol metabolism might have an impact on the myelin assembly 
and contribute to the loss of myelin seen in Cln1 ko, Cln5 ko and Cln1/5 dko 
mice. Further studies are required to clarify the signalling pathway connections 
and possible interaction partners related in lipid metabolism. Also, lipid traffick-
ing studies focusing on cells of the CNS may give further insights into the basic 
mechanisms underlying these devastating diseases. 
5.3.5 Gene expression profiling of Cln1/5 dko mouse brain (III) 
To detect changed gene expression levels in 1 month old Cln1/5 dko mice, glo-
bal gene expression of about 45 000 genes was analysed from cortex samples. 
Statistically significant upregulation of 24 genes and downregulation of 31 
genes were detected (III; suppl. Table 2). Cyclase-associated protein 1 (Cap1, 
1.9-fold) was found to be the most prominently upregulated gene, and other 
upregulated genes included complement subcomponents C1qb (C1qb, 1.6-fold) 
and C1qc (C1qc, 1.4-fold), Fc receptor homolog S (Fcrls, 1.6-fold) and glial 
fibrillary acidic protein (GFAP, 1.5-fold). The most downregulated gene was α-
synuclein (Snca, -177.2-fold) and downregulation of oligodendrocytic myelin 
paranodal and inner loop protein (Opalin, -1.8-fold) and other myelin related 
genes (myelin and lymphocyte protein Mal, -1.6-fold, myelin associated glyco-
protein Mag, -1.6-fold, myelin oligodendrocyte glycoprotein Mog, -1.5-fold, 
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proteolipid protein Plp1, -1.2-fold and myelin basic protein Mbp, -1.2-fold) were 
also detected.  
DAVID Functional Annotation Clustering was used to study the affected path-
ways in 1 month old Cln1/5 dko mice. Pathways linked to immune response 
were upregulated, and pathways linked to myelin ensheathment and nerve im-
pulse transmission were downregulated (III; suppl. Table 3). These findings are 
consistent with detected changes in nerve ensheathment and myelination, and 
upregulation of inflammation associated pathways in Cln1 ko mouse brain and 
neuron cultures (Ahtiainen et al., 2007; von Schantz et al., 2008). The Cap1 is a 
gene, which is upregulated in all three mouse models (Cln1 ko, Cln5 ko and 
Cln1/5 dko) plays an important role in neuronal growth cone-cytoskeletal dy-
namics (Ahtiainen et al., 2007; von Schantz et al., 2008; III). The gene expres-
sion analysis data is in line with the results from immunohistochemical studies, 
which revealed glial activation and loss of cortical myelin in Cln1/5 dko mouse 
brains (III; Figure 3-4; see 5.3.3). Hence, these findings seem to be accurate 
and relate to the disease progression.  
The downregulation of the α-synuclein gene expression in Cln1/5 dko mouse 
cortex was not detected in single knockout mouse models previously. To analyse 
if the α-synuclein is downregulated at the protein level as well, immunohisto-
chemical staining of α-synuclein in wt, Cln1 ko, Cln5 ko and Cln1/5 dko brain 
sections were performed. Reduced α-synuclein staining in the cortical neuropil 
of Cln1/5 dko mice was observed, but not in thalamic regions (III; Figure 7). 
Western blotting of whole brain lysates from 1 month old mice showed highly 
reduced α-synuclein protein expression in three out of five Cln1/5 dko brain 
lysates, but was always present in wt and the single knockout mouse brain sam-
ples (III; Figure 7). This variation might reflect the decreased α-synuclein ex-
pression detected in the cortex, but probably not in the thalamus. α-synuclein has 
been reported to be upregulated in many neurodegenerative diseases (Vekrellis 
et al., 2011) and was shown to be upregulated in cultured neurons of previously 
reported Cln1 ko mouse model (Ahtiainen et al., 2007). However, this model 
was in a different background than the one used in study III and cultured neu-
rons instead of mouse cortex were studied. It has been reported that α-synuclein 
is a presynaptic protein, which plays a role in the regulation of dopaminergic 
transmission, synaptic plasticity, and vesicle trafficking (Ruiperez et al., 2010; 
Uversky, 2008). Mice lacking α-synuclein display neurochemical, electrophysi-
ological, and behavioural defects (Abeliovich et al., 2000). Lipid-binding was 
suggested for α-synuclein as another function (Chua and Tang, 2011). Hence, α-
synuclein and lipid metabolism might be involved in NCL pathology in general. 
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In summary, the findings of the gene expression analysis supply additional 
information about the pathways affected in the early stages of NCL diseases. 
Overall, NCL proteins may be involved in the development of the nervous sys-
tem. 
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6 Conclusions and future prospects 
In the past 10 years the pathology and molecular biology of the proteins behind 
CLN1 and CLN5 diseases have been studied using mouse and cell models and have 
furthered our understanding of these devastating diseases. When this PhD project 
was initiated, the in vitro function and 3D structure of CLN1/PPT1 had been de-
scribed and the pathology of Cln1 ko mice had been extensively studied. In contrast, 
less was known about the CLN5 protein. For example, localisation and solubility 
was discussed controversially. This project was initiated to clarify the maturation 
and localisation in the cell of normal and mutated CLN5 protein, to further charac-
terise the pathology of Cln5 ko mice and to analyse the Cln1/5 dko mouse model in 
order to gain new insights behind NCLs in general. 
One major finding of this project was on the maturation of the CLN5 protein. It was 
shown that the four pre-proforms of CLN5 undergo N-terminal signal peptide cleav-
age in the ER. All constructs resulted in one proform independent of the position of 
the starting methionine (M1-M4). The proform of CLN5 then acquires high man-
nose sugars in the ER, traffics further to the TGN, where complex type sugars are 
added. Finally the protein traffics to the lysosomes via MPR-dependent or independ-
ent pathways. These results lead to further questions which need to be clarified: for 
example, which is the MPR-independent route to the lysosomes? Also, the structure 
and function of the CLN5 protein remain unknown. Further, the gene expression 
levels of Cln5 in cells of the CNS were measured. It was found that Cln5 expression 
levels were highest in cultured microglia from C57BL/6JRcc mice. Also, it was 
shown that Cln5 expression rises gradually in these mice up to 3 months of age and 
then reaches a plateau. However, the question remains if the mRNA levels reflect 
the protein levels. Further, it would be interesting to study if Cln5 expression de-
creases at older age points than 5 months. If there is any functional defect in microg-
lia caused by loss of functional Cln5, also needs to be assessed in the future.  
Another major finding was the link between Cln5 and lipid metabolism. First evi-
dence was provided that Cln5-deficiency leads to disturbed systemic cholesterol and 
BODIPY-Lactoceramide transport. It remains to be studied whether this defect is a 
direct or secondary effect and if the lipid transport within the CNS is affected. How-
ever, these results pinpoint to a connection between CLN5 and lipid metabolism in 
serum lipid components and peritoneal macrophage lipid transport. Interestingly, it 
has been shown that patients with MS display early cortical demyelination (Luc-
chinetti et al., 2011). This observation was confirmed in this thesis work in Cln5 ko 
mice as well. Lucchinetti et al., (2011) suggest that cortical neuron loss may be di-
rectly linked to inflammatory demyelination, and hence recommend attempts to 
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inhibit inflammation to protect neurons. This is an interesting aspect which might be 
helpful for CLN5 patients or even for NCL diseases in general.  
Herein, it was presented that CLN1/PPT1 can rescue the lysosomal trafficking of all 
analysed mutated CLN5 constructs in vitro. It was shown earlier that CLN1/PPT1 
and CLN5 can interact in vitro and gene expression studies of Cln1 ko and Cln5 ko 
mouse brains pinpointed to common affected pathways (Lyly et al., 2009; von 
Schantz et al., 2008). Now, the basic characterisation of the newly generated Cln1/5 
dko mice further underlined the possible interactions of Cln1 and Cln5 gene pro-
ducts, as loss of both genes caused a more severe clinical NCL phenotype in these 
mice than in the single-knockouts. Enhanced accumulation of autofluorescence ma-
terial, enhanced astrocytosis and microglial activation, defects in cortical myelina-
tion and the GROD ultrastructure in Cln1/5 dko mice closer resemble the more se-
vere pathological features of Cln1 ko mice than Cln5 ko mice, while the onset of 
neuronal loss closer resembles Cln5 ko mice.  
Finally, it was demonstrated in this thesis work that reactive astrocytosis and 
microglial activation precede neuronal death in Cln5 ko and in Cln1/5 dko mice. 
Glial cell pathology has been recognised before in several CNS degenerative dis-
orders. Therefore, it may be that the basic causes in CLN5 disease are dysfunctions 
in glial cells leading to a disturbed cross-talk between neurons and glia, which in 
turn leads to neurodegeneration. Neuron-glia interaction studies and functional ana-
lyses of these diverse cells of the CNS are required to gain more insights into NCLs 
in general. As microglia and astrocytes seem to play an important role in the pathol-
ogy of CLN5 it would be interesting to investigate the integrity of the blood-brain-
barrier (BBB) in Cln5 ko mice. For instance, the cortex is highly vascularised and 
the BBB is affected in many neurodegenerative diseases (Baeten and Akassoglou, 
2011), and has been very recently shown to be affected in a Cln1 ko mouse model 
(Saha et al., 2012).  Further, it would be important to check, whether some sort of 
peripheral cell recruitment to the affected BBB then takes place (e.g. leucocytes) due 
to a potential defective BBB in Cln5 deficient models. A very recent publication has 
proposed a mechanism behind neurodegeneration (Sundaram et al., 2012). They 
report that cyclin-dependent kinase 5 (Cdk5) is deregulated by p25 in several neu-
rodegenerative diseases such as PD and AD (Sundaram et al., 2012). Further, Sun-
daram et al. propose that hyperactivation of p25/Cdk5 leads to upregulation of 
phospholipase A2 (PLA2). PLA2 hydrolyses phosphatidylcholine to a soluble lipid 
factor lysophosphatidylcholine (LPC), which in turn activates glia to produce cyto-
kines/chemokines and causes leucocytes to infiltrate the brain and subsequently 
trigger neurodegenerative disease progression. Whether this p25/Cdk5/LPC signal-
ling plays a role also in NCL disease progression would be essential to be assessed. 
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It is known that astrocytes and microglia screen along the BBB. Astrocyte scars can 
be an attempt of neuroprotection to form barriers for microglia (Baeten and Akasso-
glou, 2011). Additionally, recent results indicate that astrocyte attenuation of Cln1 
ko mice by generating a GFAP/Vimentin/Cln1 triple knockout mice exabertates 
neuroinflammation in the CNS (Macauley et al., 2011). Therefore, they suggest a 
protective role for the upregulation of the intermediate filaments (vimentin and 
GFAP) in Cln1-deficiency, which might be a general phenomenon in NCLs and 
common in neurodegenerative diseases. Further, our studies present that two NCL 
mouse models share several features, like microglial activation, lipid disturbances 
and reactive astrocytosis, which are universal features for most neurodegenerative 
diseases and even are exabertated when both genes are dysfunctional. As defective 
cortical myelination is also found in MS patients, this may implicate that this pa-
thology might be a common feature in NCLs or even in neurodegenerative diseases. 
No therapeutic attempts have been made for CLN5 disease so far, but as CLN5 pro-
tein is a soluble lysosomal enzyme, combination of different therapy forms might be 
a fruitful approach. Combination therapy has been very recently reported to be ex-
tremely beneficial and superior to single therapy approaches in Cln1 ko mice 
(Macauley et al., 2012; Roberts et al., 2012). Cln1 ko mice were treated with adeno-
associated virus (AAV) 2/5-PPT1 mediated gene therapy in combination with the 
systemic delivery of the lysosomotropic PPT1 mimetic phosphocysteamine (Roberts 
et al., 2012). Also, a second approach using AAV2/5-PPT1 mediated gene therapy 
in combination with bone marrow transplantation in newborn Cln1 ko mice was a 
fruitful approach (Macauley et al., 2012). The treated Cln1 ko mice presented bio-
chemical and histological improvements, their lifespan was dramatically increased, 
and motor function was sustained. These findings are substantial for the develop-
ment of therapeutic strategies to find a cure for NCLs patients in the future. More-
over, iPS cell research might be beneficial for the development of therapies as these 
cells have characteristics of self-renewal and pluripotency, which makes disease 
modelling, drug screening, and cell replacement therapy possible (Jung et al., 2012). 
Neurons have been differentiated from iPS cells and represented the in vivo pheno-
type in Parkinson’s disease (Jung et al., 2012). In this case, iPS cell derived do-
paminergic neurons gave a positive therapeutic effect in a rodent Parkinson's disease 
model (Jung et al., 2012). Disease specific iPS cells could be derived from CLN5 
patients and be utilised for drug screenings, disease modelling and may be even used 
for cell replacements therapy in the future. 
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